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1     Introduction 
 
1.1 Ataxin-3 
 
1.1.1 Structure, expression, localization and posttranslational modifications of ATXN3  
 
The human Machado-Joseph-Disease (MJD) or Ataxin-3 (ATXN3) gene was first described 
by Kawaguchi et al. in 1994. It is located in the region 14q24.3-q32.2 on the long arm of 
chromosome 14 and comprises 48070 base pairs (NG_008198.2 RefSeqGene, pubmed; 
Takiyama et al., 1994). The gene consists of 11 exons with the start codon in exon 1 and a 
repeat of the nucleotides cytosine, adenine and guanine (CAG repeat stretch) in exon 10.  
So far, 56 different splice variants of ATXN3 have been identified of which about 20 
represent protein-coding mRNAs (Bettencourt et al., 2010; Ichikawa et al., 2001; Kawaguchi 
et al., 1994). The most frequently expressed isoform in the brain consists of 11 exons which 
are translated into an ATXN3 protein of 361 amino acids, based on a CAG repeat length of 
13 (Harris et al., 2010; Schmidt et al., 1998; Trottier et al., 1998; Ensembl transcript ID 
ENST00000393287). The CAG repeat, located in exon 10, is translated into a poly glutamine 
(polyQ) repeat sited at the C-terminus of the corresponding protein. 
Structurally, the protein consists of a conserved, globular deubiquitinating N-terminal 
Josephine domain (JD) with a papain-like fold and a more flexible C-terminal tail containing 
two ubiquitin-interacting motifs (UIMs) and a polyQ stretch (Albrecht et al., 2004; Burnett et 
al., 2003; Hofmann et al., 2001; Mao et al., 2005; Masino et al., 2003). One splice variant 
contains a putative third UIM at the end of the C-terminus (Goto et al., 1997; Fig. 1.1 A). 
ATXN3 is a small protein with a molecular weight varying around 42 kDa, depending on the 
size of the polyQ repeat.  The normal form of ATXN3 contains repeats with a range from 12 
to ~ 43 whereas the mutated exceeded stretch contains nearly always 60 or more repeats 
(Fig. 1.1 B; Cancel et al., 1995; Durr et al., 1996; Maciel et al., 1995; Matilla et al., 1995; 
Matsumura et al., 1996b; Ranum et al., 1995; Sasaki et al., 1995).  
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Figure 1.1: Normal and mutated forms of ATXN3  
A: Schematic representation of the protein ATXN3. The protein consists of 361 amino acids with an N-
terminal Josephin domain that contains two nuclear export signals (NES).  The C-terminal part 
contains three ubiquitin interacting motifs (UIM 1 to 3), a nuclear localization signal (NLS) and the 
variable polyQ repeat (Qn). B: Schematic overview of a normal and mutated ATXN3 gene with 
different CAG repeat numbers and the corresponding proteins with differences in the length of the 
polyQ stretch. 
 
The normal as well as the mutated form of ATXN3 are ubiquitously found throughout the cell 
and are equally expressed in different neuronal subpopulations within the brain, e.g. purkinje 
cells of the cerebellum or in neurons of the ventral pons (Paulson et al., 1997a and b).   
In most neurons, ATXN3 has a cytoplasmic, dendritic, and axonal localization (Trottier et al., 
1998). But it was also shown that ATXN3 is able to translocate from the cytoplasm to the 
nucleus and back. (Chai et al., 2002; Paulson et al., 1997; Pozzi et al., 2008; Schmidt et al., 
1998; Tait et al., 1998; Todi et al., 2007; Trottier et al., 1998). Different regions might be 
implicated in regulating ATXN3 cellular localization such as a C-terminal nuclear localization 
signal (NLS) in the proximity of the polyQ repeat and two nuclear export signals (NES; 
Albrecht et al., 2004; Antony et al., 2009; Breuer et al., 2010; Macedo-Ribeiro et al., 2009; 
Fig. 1.1 A). 
Furthermore, ATXN3 comprises different phosphorylation sites, which might also be involved 
in influencing the nuclear localization as it was shown for the casein kinase 2 (CK2) mediated 
phosphorylation of serines 236, 340 and 352 (Mueller et al., 2009). Reina et al. (2010) 
showed that heat shock-mediated proteotoxic stress leads to the translocation of ATXN3 into 
the nucleus after phosphorylation of serine 111. In addition to the nuclear localization, it was 
further shown that phosphorylation of ATXN3 is also important for the protein stability 
(Mueller et al., 2009). 
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1.1.2 Physiological roles of ATXN3  
 
As mentioned before, ATXN3 is composed of a globular N-terminal Josephin domain (JD) 
followed by a flexible C-terminal tail (Masino et al., 2003). Both parts are involved in a 
number of different physiological functions within the cell. The JD is known to have an 
isopeptidase activity suggesting ATXN3 to be involved in the ubiquitin-proteasomal pathway 
(Burnett and Pittman, 2003). Thereby the JD in combination with the C-terminal UIMs can 
either rescue proteins from degradation or initiate breakdown due to deubiquitinating events 
(Burnett and Pittman, 2003; Winborn et al., 2008). Additionally to its involvement in protein 
degradation, ATXN3 has been shown to regulate transcriptional processes by interacting 
with several transcription factors and histones and is able to influences gene expression 
(Evert et al., 2006; Li et al., 2002). Furthermore, ATXN3 was shown to be involved in 
aggresome formation (Burnett and Pittman, 2005), microtubule stabilization (Rodrigues et al., 
2010) and myogenesis (do Carmo Costa et al., 2010).  
The different physiological functions of ATXN3 will be described in more detail in the next 
sections.   
 
 
1.1.2.1 ATXN3 is a deubiquitnating enzyme (DUB) 
 
ATXN3 is a deubiquitinating papain-like cysteine protease in the ubiquitin proteasome 
system (UPP), representing the main cellular mechanism for the turnover of short-lived or 
damaged proteins (Albrecht et al., 2004; Doss-Pepe et al., 2003; Scheel et al., 2003). The 
catalytic site of ATXN3 consists of a triad with cystein 14, histidin 119 and asparagine 134 in 
the Josephin domain (JD), which is, in contrast to other cysteine proteases, constitutively 
active and does not need cation-induced conformational changes for its activation (Albrecht 
et al., 2004).  
In order for damaged proteins to be prepared for degradation by proteasomes, ubiquitins 
(Ub) have to be covalently attached individually or as a poly-ubiquitin chain to one or several 
lysine residues of target proteins. DUBs can trim polyUb chains down to 4/5 moieties for 
optimal recognition by proteasomes or completely remove Ub chains to rescue substrates 
from degradation (Reyes-Turcu et al., 2009; Reyes-Turcu and Wilkinson, 2009). Those 
mechanisms of editing and removal of poly-ubiquitin chains as well as recycling of ubiquitin 
are critical for cellular homeostasis. 
Inhibiting the deubiquitinating activity of ATXN3 results in an increase of polyubiquitinated 
proteins, which supports the idea of ATXN3 being involved in the interactions with 
polyubiquitinated proteins targeted for proteasomal degradation (Berke et al., 2005; Schmitt 
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et al., 2007).  
Binding of ubiquitin chains by ATXN3 occurs at two adjacent but distinct ubiquitin binding 
sites within the JD and the two or three C-terminal UIMs (Burnett et al., 2003; Chai et al., 
2004; Nicastro et al., 2009). ATXN3 preferentially binds the poly-ubiquitin linkages lysine 63 
and with less affinity, the poly-ubiquitin linkages lysine 48. And it displays even higher activity 
toward mixed 48- and 63-linkage polyubiquitin (Winborn et al., 2008). Thereby ATXN3 
recognizes polyUb chains of four or more ubiquitin monomers (Berke et al., 2005; Burnett et 
al., 2003). 
It was further suggested that ATXN3 functions as a polyUb-editing protease. Instead of a 
complete disassembly of polyUb chains, a shortening of the chain is preferred in order to 
yield free Ub and to trim chains down to four residues for optimal proteasomal recognition 
(Burnett et al., 2003; Burnett and Pittman, 2005; Kuhlbrodt et al., 2011; Nicastro et al., 2010; 
Winborn et al., 2008).  
A cooperative interplay between the UIMs and the two Ub-binding sites of the JD in order to 
cleave Ub chains was suggested by Nicastro et al. (2010): the UIMs might help to recruit and 
bind the polyubiquitinated substrates and the two Ub-binding sites may align the position of 
the isopeptide bonds relatively to the catalytic site in a way that allows for a sequential 
editing. In contrast, for the regulation of the dub activity itself, the catalytic activity of ATXN3 
is UIM independent and can be enhanced via monoubiquitination of ATXN3 without the 
presence of any co-factors (Todi et al., 2009). 
Furthermore, the length of the CAG repeat does not influence the deubiquitinating function of 
ATXN3 (Masino et al., 2004; Tzvetkov and Breuer, 2007).  
In summary, these observations support the conclusion that ATXN3 acts as a 
deubiquitinating enzyme and contributes to the proteasomal degradation of proteins by the 
ubiquitin proteasome machinery.  
 
 
1.1.2.2 Ataxin 3 regulates the retrotranslocation of ERAD substrates and is important 
for the protein quality control 
 
The efficient clearance of misfolded proteins is essential to ensure cellular homeostasis by 
preventing the accumulation of toxic protein species. For this, chaperones as well as 
ubiquitin-proteasome systems (UPS) are essential. Chaperones are involved in folding and 
refolding processed of proteins and the UPS is mandatory for degradation of misfolded 
proteins. Several ATXN3 interacting partners have been discovered so far, providing 
information about the protein’s functions in the protein quality control.  
ATXN3 binds the p97/valosin-containing protein (VCP) through the C-terminal 
arginine/lysine-rich motif in proximity to the polyQ repeat (Boedderich et al., 2006; 
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Hirabayashi et al., 2001; Matsumoto et al., 2004; Mao et al., 2005; Rao et al., 2017; Zhong 
and Pittman, 2006). VCP/p97 is involved in the regulation of endoplasmic reticulum-
associated degradation (ERAD), a cellular process important for the degradation of misfolded 
endoplasmic reticulum (ER) proteins (Liu et al., 2012; Zhong et al., 2006). Thereby, the 
ERAD system alleviates cytotoxic stress caused by misfolding of secretory proteins. For this 
purpose, VCP is implicated in the retrotranslocation of misfolded proteins from the ER into 
the cytoplasm for proteasomal degradation. ATXN3 forms a complex with VCP/p97 in order 
to regulate this process (Wang et al., 2006). Although ATXN3 has been associated with the 
ERAD, there is still a dispute about whether ATXN3 promotes or decreases degradation by 
this pathway (Liu et al., 2012; Wang et al., 2006; Zhong and Pittman, 2006).  
ATXN3 is further known to interact with the human homologues of yeast DNA-binding protein 
RAD23, hHR23A and hHR23B through the ubiquitin-binding site 2 of the josephin domain 
(Nicastro et al., 2005; Wang et al., 2000). Similar to p97/VCP, also hHR23A and hHR23B are 
involved in the delivery of ubiquitinated substrates for proteasomal degradation (Wang et al., 
2000).  
Ube2w and Ataxin 3 were found to coordinately regulate the ubiquitin ligase C-terminus of 
Hsc70 interacting protein (CHIP; Scaglione et al., 2011). CHIP is an E3 ubiquitin ligase which 
bridges the chaperone and UPS system by interacting with chaperones in order to 
ubiquitinate misfolded proteins, thus targeting them for proteasomal degradation. Ataxin 3 
participates in the initiation, regulation and termination of the CHIP ubiquitination cycle 
(Scaglione et al., 2011). 
When the protein quality control via proteasome is not sufficient to degrade or correct 
misfolded proteins, cells also have a deposition method: they can sequester aggregates by 
collecting them at the microtubule-organizing center (MTOC). These so-called aggresomes 
at the perinuclear region are then degraded by lysosomes, promoting the maintenance of 
cellular homeostasis.  
ATXN3 colocalizes with aggresomes and preaggresome particles as well as with proteins, 
which are involved in the transport of misfolded proteins and in the formation of aggresomes 
(Burnett and Pittman, 2005).  It is proposed that ATXN3 is responsible for the transport and 
stabilization of misfolded proteins to the MTOC as it is associated with parts of the 
cytoskeleton and transport proteins such as dynein and histone deacetylase 6 (Burnett & 
Pittman, 2005; Mazzucchelli et al., 2009; Rodrigues et al., 2010).  
Finally, also ubiquitination is implicated in the formation of aggresomes since it was shown 
that ubiquitination of ATXN3 at Lys-117 improved its ability to promote aggresome formation 
(Todi et al., 2010).  Another study suggested that trimming K63-linked polyubiquitin chains by 
ATXN3 promotes mutant superoxide dismutase 1 (SOD1) aggresome formation and vice 
versa, knockdown of ATXN3 decreases mutant SOD1 aggresome formation, thereby 
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increasing cell death induced by mutant SOD1 (Wang et al., 2012). 
Concluded, its interactions with ERAD substrates such as p97/VCP, hHR23A and hHR23B, 
with CHIP and its implications in the aggresome formation, make the deubiquitinating 
enzyme ATXN3 an important factor in the regulation of protein quality control and thus an 
important regulator for maintenance of cellular homeostasis. 
 
 
1.1.2.3 Ataxin 3 is involved in transcriptional regulation processes 
 
Besides the aforementioned roles in protein quality control mechanisms, ATXN3 has further 
been shown to play a role in the regulation of transcriptional processes. Since ATXN3 
interacts with several transcriptional regulators, the transcriptional regulation via ATXN3 
might arise through a variety of mechanisms. Known interaction partners are: TATA box-
binding protein (TBP)-associated factor 4 (TAF4; Shimohata et al., 2000), cAMP response 
element-binding protein (CBP; Chai et al., 2002; Li et al., 2002; McCampbell et al., 2000), 
p300 (Li et al., 2002), p300/CBP-associated factor (PCAF; Li et al., 2002), the transcription 
repressors nuclear receptor co-repressor (NCoR1) and histone deacetylase 3 (HDAC3)   
(Evert et al., 2006a) as well as forkhead box O (FOXO) transcription factor FOXO4 (Evert et 
al., 2006b). 
TAF4 is a transcription initiation factor, which helps coordinating processes for the initiation 
of transcription by RNA polymerase II. Expanded polyglutamine stretches of ATXN3 were 
found to interact with TAFII130, thus interfering with CREB-dependent transcription. 
CBP, p300 and PCAF are transcriptional coactivators that form complexes with other co-
activators and proteins with acetyltransferase activity. By binding these co-activators through 
its C-terminal region, ATXN3 might repress the transcription. Additionally, part of the N-
terminal region of ATXN3 binds histones, which seems to repress acetylation by blocking the 
access to histone acetylation sites (Li et al., 2002). 
In addition to interactions with transcription factors or coactivators, also direct binding of 
ATXN3 to DNA can likely take place. This might be achieved through a leucine zipper motif 
located at amino acid 223 to 270 as it was shown for the matrix metalloproteinase-2 (MMP-2) 
promoter (Evert et al., 2006). In this context it was further revealed that ATXN3 functions as 
a transcriptional co-repressor (Evert et al., 2006). ATXN3 recruits the nuclear receptor co-
repressor (NCoR1) and the histone deacetylase 3 (HDAC3) resulting in complexes, which 
are able to deacetylate the MMP2 promoter, by binding to DNA motifs in distinct chromatin 
regions of the promoter leading to the transcriptional repression. Although mutated ATXN3 
interacts with HDAC3 and NCoR as well, no deacetylating repressor complexes are formed, 
as it is the case for normal ATXN3. Consequently, no inhibition of the MMP2 transcription 
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occurs and transcription can be activated after binding of GATA-2. This mechanism 
demonstrates that ATXN3 is able to epigenetically regulate the transcription of target genes 
(Evert et al., 2006). Moreover, ATXN3 can inhibit histone acetylation and repress 
transcription in vivo via interaction with the polyQ repeat (Li et al., 2002). 
The transcription factor FOXO4 is important for the regulation of many cellular pathways 
including oxidative stress signaling, longevity, insulin signaling, cell cycle progression, and 
apoptosis (Araujo et al., 2011). It was shown that ATXN3, as a transcriptional co-activator 
together with FOXO4, is involved in the regulation of the superoxide dismutase 2 (SOD2) 
gene expression. Thereby, ATXN3 directly interacts with FOXO4 and binds in vivo the 
endogenous SOD2 gene promoter in proximity to the FOXO4 consensus motif. Thus, normal 
ATXN3 enhances the FOXO4 dependent transcription of SOD2, whereas the expanded 
ATXN3 is associated with a decrease of the SOD2 expression (Araujo et al., 2011). 
In summary, ATXN3 is involved in various processes of transcriptional regulation either as a 
co-repressor, by direct binding of DNA or due to ubiquitination and deubiquitnation of 
transcription factors. The various functions of ATXN3 and its thus wide distribution in the cell 
are summarized in Fig. 1.2. 
 
   
 
 
Figure 1.2: The different roles of ATXN3 and its consequently wide distribution in the cell  
ATXN3 displays deubiquitinating (DUB) activity (A) and interacts with polyUB chains (B). It participates in protein 
homeostasis via ERAD (C). Additionally, regulation of protein quality control due to formation of aggresomes (D) 
and microtubule organization via interactions with MTOC were found (E). And ATXN3 is involved in transcriptional 
regulation processes such as regulation of histone acetylation (F). Adopted from Matos et al. (2011). 
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1.1.2.4 Ataxin 3 as a disease protein for Machado-Joseph Disease (MJD) 
 
Besides the various functions of ATXN3, the expanded form of the protein is also involved in 
the formation of nuclear inclusions (NIs). Those are exclusively present in neurons of brain 
areas such as the cerebellum, ventral pons, in the substantia nigra, globus pallidus, dorsal 
medulla and dentate nucleus (Paulson et al., 1997b). The formation of NIs was reproduced in 
cell and animal models overexpressing mutant ATXN3 (Ikeda et al., 1996; Schmidt et al., 
2002). NIs are heavily ubiquitinated, protein aggregates, which are most likely formed due 
conformational changes of the expanded polyQ stretch in the C-terminus of ATXN3. In 
addition to polyQ-expanded ATXN3, NIs also sequester several other proteins, including 
members of the cell quality control systems such as proteasome constituents, transcription 
factors including TATA-binding protein (TBP), ubiquitin and molecular chaperones, which 
might be recruited to prevent ATXN3 misfolding and aggregation (Chow et al., 2004; Paulson 
et al., 1997b; Schmidt et al., 2002; Seidel et al., 2010). The decrease of free availability of 
these proteins may promote cytotoxicity within the cell through different possible 
mechanisms: impairment of transcription (Chai et al., 2002; McCampbell et al., 2000), 
disturbances of the quality control systems of the cells (Muchowski et al., 2000; Paulson et 
al., 1997b; Schmidt et al., 2002; Warrick et al., 1999), hindrance of axonal transport 
(Gunawardena et al., 2003) and disturbances caused by recruitment of Ub-binding proteins 
or other polyQ-containing proteins (Donaldson et al., 2003). All of these altered and 
dysregulated cellular functions are reflected in the phenotype of patients suffering from 
Machado-Joseph Disease (MJD), a disease, which is caused by ATXN3.  
Machado Joseph Disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3) is an 
autosomal dominant neurodegenerative disease of late onset and the most frequent form of 
ataxia in humans (Schöls et al., 1995, 2004). It was first described in two families of 
emigrants from the Azorean islands based on the clinical phenotype and named after those 
families (Nakano et al., 1972; Rosenberg et al., 1976). In the 90s genetic testing showed that 
MJD and the spinocerebellar ataxia of type 3 (SCA3) are based on the same gene defect 
(Haberhausen et al., 1995). Nowadays it is known that the hereditary disease exists 
worldwide and affects all ethnicities. Although the official Human Genome Organization 
(HUGO) name for this disease is MJD, it is also termed SCA3 or MJD/SCA3 in the literature 
(Paulson H, 2012). 
Kawaguchi et al. (1994) discovered that MJD originates from an expansion of CAG repeats 
in exon 10 of the MJD1 gene, which leads to a C-terminal elongated polyglutamine (polyQ) 
tract of its gene product ATXN3. This makes MJD a member of a group of in total nine polyQ 
diseases, including Huntington’s disease (HD), dentatorubral-pallidoluysian atrophy 
(DRPLA), spinal and bulbar muscular atrophy (SBMA) and spinocerebellar ataxia (SCA) 
types 1, 2, 3 6, 7 and 17 (Gatchel and Zoghbi, 2005; Shao and Diamond, 2007; Zoghbi and 
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Orr, 2000).  
Regarding the CAG tract it was revealed that its length is negatively correlated with disease 
onset resulting in variations of age of onset between 5 to 70 years (Maciel et al., 1995; 
Paulson H, 2012; van de Warrenburg et al., 2002) and a positive correlation with the severity 
of the disease. As mentioned before, the normal form of ATXN3 contains repeats with a 
range from 12 to ~ 43 whereas the mutated exceeded stretch contains about 60 or more 
repeats. Furthermore, scarce intermediate expansions with 45 to 59 repeats might either 
manifest as a mild form of ataxia, as restless leg syndrome or does not lead to any 
symptoms (Gu et al., 2004; Padiath et al., 2005; Takiyama et al., 1995; Van Alfen et al., 
2001). 
The ubiquitous expression of ATXN3 results in progressive dysfunction in many regions and 
pathways, such as the brainstem, pyramidal and extrapyramidal pathways, lower motor 
neurons, oculomotor system and peripheral nerves (Cancel et al., 1995; Durr et al., 1996; 
Matusmura et al., 1996; Rub et al., 2004; Sasaki et al., 1995; Takiyama  et al., 2004).  
Although the core clinical feature in MJD is progressive ataxia due to cerebellar and 
brainstem dysfunction, there is a wider range of symptoms observed in MJD. This includes 
vestibular and speech difficulties after onset of the disease and visual and oculomotor 
problems including nystagmus, slowing of saccades, disconjugate eye movements, 
spasticity, and ophthalmoplegia with disease progression. In advanced stages of disease, 
patients are wheelchair-bound and suffer from dysarthria and dysphagia (Paulson H, 2012). 
The clinical phenotype worsens in cases with homozygous heredity suggesting a gene 
dosage effect (Carvalho et al., 2008). So far, there is no cure for the disease and survival 
after disease onset ranges from ~20 to 25 years (Klockgether et al., 1998). 
In accordance with the symptoms, signs of neurodegeneration such as brain atrophy and 
neuronal loss are widespread and variable, most often involving regions of the hindbrain 
such as deeper structures of the basal ganglia, various brainstem nuclei and the cerebellum 
(Koeppen et al., 1999; Paulson HL 2007, 2012; Rub et al., 2004).  
 
 
 
1.1.2.5 The ‘loss of function’ and ‘gain of function’ hypothesis for Machado-Joseph 
Disease 
 
As mentioned above, there are some evidences, such as an increase in disease severity and 
a decrease in the age of onset with a higher repeat number, suggesting that the unstable 
expansion of the polyQ repeat of ATXN3 is responsible for the emergence of the pathology 
of MJD. Additionally, several transgenic models expressing polyQ sequences outside the 
natural gene environment displayed a neurodegenerative phenotype (Ikeda et al., 1996; 
Paulson et al., 1997b).  But so far, the mechanism how polyQ expanded ATXN3 causes the 
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pathogenesis of MJD, is still a matter of intensive debate.  
One important argument for the idea that polyQ containing aggregates are responsible for 
the pathology of MJD is that they recruit and sequester more Ataxin 3 and numerous other 
cellular proteins (Chai et al., 2002; Donaldson et al., 2003). In this case, these proteins would 
be hampered in fulfilling their functions, leading to disturbances of important cellular 
processes, promoting a potential ‘Loss of Function’ hypothesis.  
The ‘Gain of Function’ hypothesis on the other hand proposes that the proteolytic cleavage of 
the expanded polyglutamine stretch in the ATXN3 protein leads to the generation of cytotoxic 
and aggregation-prone shorter soluble fragments, forming intranuclear inclusions (Berke et 
al., 2004; Haacke et al., 2006; Takahashi et al., 2008). These aggregates might interfere with 
the normal activity of the nucleus causing the cell to degenerate and die. This theory was 
previously investigated in our institute. It was found that glutamate-induced excitation of 
patient-derived neurons initiates Ca2+-dependent proteolysis of ATXN3 followed by the 
formation of SDS-insoluble aggregates. This phenotype could be abolished by calpain 
inhibition, confirming a key role of this protease in ATXN3 aggregation (Koch et al, Nature, 
2011). Regarding the two hypotheses, conformational changes of ATXN3, aggregation 
formation of whole protein or proteolytic cleave products mediate cellular mechanisms and 
function, which might cause cell death (Fig. 1.3) 
 
 
Figure 1.3: Mechanisms of 
ATXN3 toxicity. 
The conformational changes 
caused by the polyQ stretch may 
disturb the biologic function of 
ATXN3, thereby compromising 
the protein homeostasis system, 
the cytoskeleton or hindering 
transcription. Aggregation of 
whole protein or toxic fragments, 
products of proteolytic cleavage 
by calpains, can lead to 
membrane destabilization and the 
impairment of protein 
sequestration mechanisms. 
Those impairments of cellular 
functions and homeostasis finally 
induce cell death. Scheme from 
Matos et al. (2011). 
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1.1.2.6 Implications of Ataxin 3 in cellular stress responses  
 
While aggregation due to mutated ATXN3 is responsible for the pathology of MJD, non-
expanded ATXN3 was shown to be involved in multiple cellular functions, including 
transcriptional regulation and helping to maintain protein homeostasis via deubiquitination of 
target proteins or ubiquitin-editing processes (Berke et al., 2005; Matos et al., 2011; Reyes-
Turcu et al., 2009; Reyes-Turcu and Wilkinson, 2009). Additionally, there is also evidence 
suggesting that the biological function of ATXN3 might further be connected to cellular 
systems of stress response.  
An important indicator for this hypothesis is the fact that ATXN3 shifts to the nucleus in 
response to proteotoxic stress (Mueller et al., 2009; Reina et al., 2010) and furthermore that 
some types of cellular stress increase ATXN3 ubiquitination, consequently increasing its 
activity (Todi et al., 2009). More precisely, ATXN3 activity as a deubiquitinating enzyme, 
participating in protein homeostasis pathways might be important for cellular stress 
response, since it is important in dealing with stress-induced misfolded proteins, which might 
also be responsible for an exacerbation of cellular stress. In C. elegans, the orthologs of 
ATXN3 and p97/VCP (CDC-48) were shown to synergistically mediate both stress responses 
and longevity, depending on the deubiquitylation activity of ATXN3. Thus, a mechanistic link 
between protein degradation and longevity through editing of the ubiquitylation status of 
substrates involved in insulin–IGF-1 signaling was suggested (Kuhlbrodt et al., 2011). While 
investigating potential roles of ATXN3 in response to cellular stress, it was also shown that 
ATXN3 as a DUB regulated basal level of hsp70 and modulated hsp70 in response to a 
subset of cellular stresses (Reina et al., 2012).   
It was further demonstrated that ATXN3 might play a role in the stress response not only due 
to its DUB- and ubiquitin-binding functions, but also due to transcriptional regulation. After 
application of the oxidative stressor H2O2 it was shown that ATXN3 interacts as a redox-
sensitive, transcriptional coactivator with the forkhead box O (FOXO) transcription factor 
FOXO4 and activates the FOXO4-dependent transcription of the antioxidant enzyme 
manganese superoxide dismutase (SOD2) gene. But in comparison to normal ATXN3, 
mutant ATXN3 displayed a reduced capability to activate the FOXO4-mediated SOD2 
expression and further interfered with binding of FOXO4 to the SOD2 gene promoter (Araujo 
et al., 2011).  
Another proteotoxic stimulus could be the presence of misfolded and/or aggregated 
expanded ATXN3 by itself, resulting in cellular stress. Additionally, stress induced transport 
to the nucleus might trigger even more serious consequences to the cell, since ATXN3 is 
protected from degradation and enhances toxicity after nuclear localization (Bichelmeier et 
al., 2007; Breuer et al., 2010).  In terms of this theory, it was shown that aging and a possible 
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dysfunction of ATXN3 caused by the unstable expansion resulted in an inability for ATXN3 to 
protect against proteotoxic stress, leading to cell toxicity (Reina et al., 2010). Moreover, as a 
result to thermal stress, expanded ATXN3 shifted to the nucleus in a CK2-dependent 
manner, triggering and/or enhancing cytotoxic effects (Mueller et al., 2009).  
In summary, normal ATXN3 might contribute to the regulation of the cellular response to 
stress, whereas expanded ATXN3 might display an impaired stress response and might 
even worsen already toxic effects. 
 
 
1.2 Genome engineering in human cells 
 
Genome-engineering tools facilitate site-specific genetic changes of the DNA such as 
deletions, insertions, inversions and replacements. These manipulations are often necessary 
to understand how genes are functioning within a given cellular context, to investigate gene 
regulation mechanisms and to model human disease conditions using either in vitro cellular 
models or in vivo model organisms. 
The discovery of the DNA double helix in 1953 induced the development of the genome 
engineering field, with various technologies for the manipulation of DNA to be created. 
Furthermore, since the discovery that cells have an endogenous machinery to repair lethal 
double-strand DNA breaks (DSBs), researchers focused on approaches to introduce precise 
breaks in the genomic locus of DNA where changes were to be introduced (Doudna and 
Charpentier, 2014). For this two different pathways are crucial:  homology-directed repair 
(HDR) and nonhomologous end-joining (NHEJ).  
HDR requires an exogenously homologous DNA sequence to guide repair and to insert 
specific point mutations or desired sequences through recombination of the target locus with 
the ‘donor templates’. When the homologue DNA piece is absent, the cell can use NHEJ 
instead (Pardo et al., 2009). During this repair process insertion/deletion mutations (indels) of 
various lengths can be introduced, which can disrupt the translational reading frame of a 
coding sequence or the binding sites of trans-acting factors in promoters or enhancers 
(Sander and Joung, 2014). 
More recently, protein-based systems and site-directed zinc finger nucleases (ZFNs; 
(Bibikova et al., 2001, 2003; Kim et al., 1996; Porteus et al., 2003) and TAL effector 
nucleases (TALENs; Boch et al., 2009; Christian et al., 2010; Moscou et al., 2009) were 
developed. ZFNs and TALENs are artificial fusion proteins containing an engineered DNA 
binding domain fused to a nonspecific nuclease domain from the restriction enzyme FokI. 
When targeted to paired adjacent sequences, the FokI domains of these programmable, site-
specific nucleases form a dimer that activates the nuclease activity, thus creating a DSB near 
their binding sites (Wang et al., 2016). Afterwards, the cell uses its repair mechanism for the 
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induced DSB and will incorporate the mutation.  
Although both approaches were used for site-directing genome editing, they also displayed 
various challenges for the researchers such as difficulties in designing, cloning and validating 
of those proteins for a specific DNA locus (Doudna and Charpentier 2014; Sander and 
Joung, 2014; Wang et al., 2016). Thus, the introduction of site-specific modifications in the 
genome of both, cells and model organisms has been a challenging and error-prone task so 
far. 
 
 
1.2.1 Gene editing –CRISPR/Cas9 
 
In contrast to ZFN and TALEN methods, which are based on protein-DNA interactions for 
targeting, RNA-guided nucleases (RGNs) use simple Watson-Crick base pairing between the 
engineered RNA and the target DNA site. Thus, the approach is less complex in 
development since there are no difficult processes of design, synthesis or validation. 
CRISPR (clustered regulatory interspaced palindromic repeats) was first described in 1987 
by Japanese researchers as a series of short direct repeats interspaced with short 
sequences in the genome of Escherichia coli and later in a larger number of bacteria and 
archaea (Ishino et al., 1987; Mojica et al., 2000). 
Since 2005 it is known that CRISPR systems are adaptable immune mechanisms that are 
formed by many bacteria and archae to protect themselves from phages and plasmids by the 
recognition of foreign DNA (Bolotin et al., 2005; Mojica et al., 2005; Pourcel et al., 2005). 
Other findings that CRISPR loci are transcribed and that cas (CRISPR-associated) genes 
encode proteins with putative nuclease and helicase domains lead to the conclusion that 
CRISPR-Cas is an adaptive defense system that might use antisense RNAs which have 
been incorporated in the genome, as memory signatures of past invasions (Makarova et al., 
2006).  
In 2007 experiments with Streptococcus thermophilus evidenced the adaptive immunity due 
to CRISPR. After infection of Streptococcus thermophilus with phages, resistant cells 
emerged possessing new CRISPR spacers identical with the phage genome, which caused 
the phage resistance phenotype (Barrangou et al., 2007). The requirement for the 
incorporation of spacers in the genome is an encounter with foreign DNA elements, making 
this system comparable to the adaptive immunity in higher eukaryotes.  
Three stages need to be processed for adaptive immunity: In the first stage DNA fragments 
of invading plasmids or phages are inserted into the host CRISPR locus as spacers between 
CRISPR RNA (crRNA) repeats. In the second stage precursor crRNA (pre-crRNA) is 
transcribed, translated and cleaved by Cas proteins, which generates individual sequence-
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specific crRNAs after maturation. Every crRNA is composed of a repeat part and an invader-
targeting spacer portion. In the third stage, by using crRNAs as a guide, Cas proteins 
recognize and cleave foreign nucleic acids at sites complementary to the crRNA spacer 
sequence.  
In 2012, the first study was published demonstrating that the CRISPR/Cas9 mechanism can 
be repurposed for genomic engineering and further that this system works, compared to 
previous existing genome engineering techniques, with an intriguing ease and efficiency 
(Jinek et al., 2012). Those advantages made CRISPR-Cas the most preferred tool for 
genome editing so far.  
Since type II CRISPR systems are the only ones that require just one Cas protein, namely 
Cas9, for cleavage, it is preferably used for genome engineering. Cas9 is a naturally evolved, 
RNA-guided nuclease. It recognizes its target DNA through a base-pairing interaction 
between a single guide RNA (sgRNA) and its targeted DNA strand of about 20 nucleotides.  
In addition to Cas9, the type II CRISPR systems includes a designed single guide RNA 
(sgRNA) that acts like crRNAs and two template options for DNA repair; non-homologous 
end joining or homology directed repair (Fig. 1.4). 
 
 
  
 
 
 
 
 
The Cas9 nuclease contains an RNA binding domain, an alpha helix recognition lobe (REC), 
a nuclease lobe that include the RuvC and HNH for DNA cleavage, and a protospacer 
adjacent motif (PAM) interacting site (Hsu et al., 2014; Van der Ooost et al., 2014).  
The Cas9/sgRNA complex scans the DNA for a PAM (5'-NGG) site (4,5,6). PAM is a 
component of the invading plasmid, but not of the host CRISPR locus. The absence of the 
PAM sequence at the CRISPR locus in the host genome prevents the locus from being 
Figure 1.4: CRISPR/Cas9 function 
Scheme of CRISPR-Cas9 based 
genome editing. Targeted genome 
strand breaks in the DNA can be 
repaired via the nonhomologous 
end-joining (NHEJ) repair pathway, 
which introduces insertion or 
deletions creating errors, or through 
the homologous directed repair 
(HDR) pathway, that can be used to 
recombine selected markers at 
specific sites in the genome. 
(Scheme: Waddington et al., 2017). 
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targeted by nucleases and thus prevents it from self-cleavage (Mali et al., 2013). Recognition 
of a PAM site leads to unwinding of the DNA, and allows the sgRNA to check for 
complementary DNA adjacent to the PAM site. The PAM site recognition is involved in 
activating the nuclease domains HNH and RuvC which create a double-stranded break 
(DSB) in the target DNA, leading to DNA degradation (Hsu et al., 2014; Jinek et al., 2012; 
Van der Oost et al., 2014). Cas9 releases and searches for another PAM site in case the 
sgRNA is not complementary (Sternberg et al., 2014).  
The DSB generated by Cas9 activates the NHEJ or HDR DNA repair pathways. NHEJ 
causes random insertions or deletions (indels) at its targeted site, and HDR can create 
desired mutations or indels through homologous recombination guided by donor DNA.  
Single guide RNAs can be expressed along with Cas9 nuclease in the same vector to target 
specific DNA sites for genome editing, which makes it a fast and easy approach. With this 
comparably easy to manage technique it is possible to create cell lines and model organisms 
with any mutation or knockout that is desired. 
 
 
1.3 Stem cells 
 
Depending on their potency, stem cells have the remarkable potential to develop into all 
different cell types in the body, which makes them essential for the development of complex 
organisms. In mammals, stem cells can be classified into two main groups:  embryonic stem 
cells (ES) that are able to develop all three germ layers of an organism and adult or somatic 
stem cells, which are responsible for the homeostasis and regeneration of tissues or organs 
such as the liver, hair follicles or the intestinal system (Baddour et al., 2012; Boehnke et al., 
2012; Radtke and Clevers, 2005). All stem cells are undifferentiated cells that retain the 
unique ability to both continuously self-renew and to undergo differentiation into more 
restricted and specialized progeny at the same time.  
Stem cells are further categorized by their potency, the cell’s ability to differentiate into other 
types of cells. The lowest potency is found in unipotent stem cells such as spermatogonial 
stem cells, which can only form one single lineage. In contrast, multipotent stem cells 
possess the potential to form multiple closely related and discrete cell types of one tissue 
(Weissman, 2000). Examples for multipotency are neural stem cells giving rise to neurons 
and glial cells or hematopoietic stem cells differentiating into myeloid and lymphoid lineages 
(Clements and Traver, 2013). During embryonic neurogenesis, multipotent neural stem cells 
initiate a complex pattern of consecutive cycles of symmetrical as well as asymmetrical 
division to construct the exceptional complexity of the brain (Breunig et al., 2011; Kriegstein 
and Alvarez-Buylla, 2009; Rakic, 1988; Reynolds & Weiss, 1992). During adulthood, 
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multipotent stem cells are responsible for organ homeostasis and endogenous repair 
mechanisms after injury. Moreover, only the hippocampus and the subventricular zone (SVZ) 
of the human brain have been identified to harbor multipotent neural stem cells, providing a 
limited potential of self-repair of the brain (Eriksson et al., 1998; Gage, 2000).  
Pluripotent stem cells, particularly human embryonic stem (hES) cells arise at the earliest 
stages of human development and are able to generate all three germ layers giving hES 
cells the potential to form any cell type of the body in vitro (Smith, 2001; Thomson et al., 
1998). Therefore, the usage of pluripotent cells became inevitable in regenerative medicine 
(Lovell-Badge, 2001; Tabar and Studer., 2015) as well as in the field of disease modeling, 
drug discovery and cell therapy development (Colman & Dreesen, 2009; Han et al., 2011; 
Shi et al., 2017). 
 
 
1.3.1 Human pluripotent stem cells 
 
The vast development of human stem cell science started in 1994 after the inner cell mass 
(ICM) from human blastocysts was isolated and cultured. Shortly afterwards, the derivation of 
the first hES cell lines were reported by Thomson and coworkers in 1998 (Bongso et al., 
1994; Thomson et al., 1998). These discoveries lead to the progression of this discipline and 
in the development of various methods such as immunosurgery as well as mechanical and 
laser assisted isolation in order to establish hES cell lines from the ICM of cultured blastocyst 
and the morula (Ilic and Ogilvie, 2017; Kim et al., 2005; Marteyn et al., 2011; Peura et al., 
2008; Strelchenko et al., 2004). At this time, hES were thought to be the future of 
regenerative medicine, resulting in improvements of culture conditions to meet the 
requirements for the regulations for medical products and good manufacturing practice 
(GMP) guidelines by replacing compounds of animal origin with chemical compounds (Unger 
et al., 2008).  
Furthermore, by analyzing the molecular characteristics of hES cells, broad knowledge was 
achieved to decipher the mechanisms of pluripotency (Chambers et al., 2003; Li, 2005; Niwa 
et al., 1998; Rodda et al., 2005). These efforts have been rewarded in 2006 when Takahashi 
and Yamanaka discovered that the retorviral overexpression of the four transcription factors 
(TF), Oct3/4, Klf4, Sox2 and c-Myc is sufficient to directly reprogram adult somatic cells to 
the state of induced pluripotent stem cells (iPSC; Nakagawa et al., 2008; Takahashi et al., 
2007). Those iPS cells displayed, aside from some reported reporgramming-dependent 
genomic and epigenetic aberrations, the same characteristics of self-renewal and 
differentiation potential as hES cells (Gore et al., 2011; Hussein et al., 2011; Lister et al., 
2011).  
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Following the discovery of induced pluripotency, reprogramming technology developed 
towards safer integration-free methods such as direct protein transduction or mRNA and 
mature microRNA transfection and Sendai virus. Thereby, also the number of transcription 
factors was changed within the reprogramming protocols or replaced by chemical 
compounds (Anokye-Danso et al., 2011; Fusaki et al., 2009; Miyoshi et al., 2011; Nakagawa 
et al., 2008; Schlaeger et al., 2015; Warren et al., 2010; Zhu et al., 2010). Still, approaches in 
regenerative medicine and disease modeling the search for protocols for efficient 
differentiation of pluripotent cells in vitro into authentic somatic cell types such as insulin 
producing beta cells, cardiac myocard, as well as neural stem cells, neurons and glial cells 
remain a key task. 
Nevertheless, the emergence of iPS cell technology with non-embryonic origin revolutionized 
the stem cell field as it circumvents ethical and legal issues connected to hES cell research 
and allows the generation of any cell type from any individual in unlimited quantities.  
 
 
1.3.2 Differentiation potential of human pluripotent and neural stem cells 
 
 
Human pluripotent stem cells (hPSCs) represent the most immature cell population, having 
the potential to differentiate into all three embryonic germ layers (Thomson et al., 1998). 
During the last decade, the translation of basic knowledge from developmental neurobiology 
has helped to create protocols for the generation of distinct neural cell types from hPS cells.  
In the earliest protocols, hPS cells were sequentially exposed to a cocktail of extrinsic factors 
to straightly direct them into a mature neural cell type such as neurons and glia. Those ‚run-
though’ protocols comprised some disadvantages such as the generation of incompletely 
differentiated cultures and batch-to-batch variations due to time-consuming differentiation 
protocols (Kim et al., 2011). Also, for experimental validations and repetitions, the cell 
number generated by those protocols was too low, which made the reproducibility of 
experiments very difficult (Reinhardt et al., 2013). Therefore, protocols were developed to 
generate intermediate cell populations: transiently emerging neural stem cells (NSCs), which 
have the capability to both efficiently form mature neural cell types and robustly expand to 
produce a sufficient cell number. Two examples are rosette-forming neuroepithelial stem 
cells (Elkabetz et al. 2008; Koch et al. 2009) and primitive pre-rosette neuroepithelial stem 
cells (Li et al. 2011; Reinhardt et al. 2013), which can be aligned to specific stages of human 
neurodevelopment and differ in morphology, self-renewal capacity and differentiation 
potential (Conti and Cattaneo, 2010; Karus et al., 2014).  
Rosette-forming neuroepithelial stem (r-NES) cells develop after spontaneous conversion of 
early neuroepithelium (NE) precursor cells, which depends on SHH and Notch agonists when 
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kept in culture for a few passages (Elkabetz et al., 2008). These cells express the rosette-
markers PLZF and Dach1, form characteristic rosette structures with apical ZO1 expression 
and show interkinetic nuclear migration, characteristics similar to early neural tube forming 
cells (Elkabetz et al., 2008; Zhang et al., 2001). Furthermore, it was shown that exposure to 
the mitogens FGF2 and EGF and B27 supplement mix generates a homogenous and stable 
rosette-type long-term self-renewing NE stem cell population (lt-NES cell; Koch et al., 2009; 
Nemati et al., 2010). This cell population can be differentiated into glial or neuronal cells with 
highly reproducible neuronal differentiation rates and display a stable neurogenic 
differentiation pattern even after propagation for over 100 passages. Furthermore, lt-NES 
cells remain susceptible to morphogens such as Sonic hedgehog (SHH), FGF8 and retinoic 
acid, facilitating the targeted generation of different subtypes such as midbrain dopamine 
neurons or spinal motor neurons even after long-term cultivation (Falk et al., 2012; Koch et 
al., 2009). Compared to hESC, these cells exhibit significantly shorter doubling times (38 vs. 
51-81 hours) and a higher clonogenicity.  
The pre-rosette neuroepithelial stem cells were reported by Reinhardt et al. (2013) and are 
derived and propagated by using only small molecules (small molecule neural precursor 
cells; smNPCs). Their maintenance of self-renewal relies on inhibition of BMP/TGFβ 
signaling and activation of Wnt and SHH, a combination that is distinct from FGF2 and EGF 
required for lt-NES cells. Furthermore, smNPCs can be efficiently specified into neural tube 
and neural crest lineages, which gives them a developmental potential upstream of lt-NES 
cells. It was further demonstrated that culturing smNPCs with FGF2 results in the formation 
of rosette-like structures, which have been previously associated with the neural plate-stage 
of embryogenesis. Compared to ltNES cells smNPCs can be cultured at a wide range of cell 
densities since they can grow clonally, thus facilitating the handling since less splitting steps 
are required. 
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1.4 Aim of this study 
 
Transcriptional regulation is an essential cellular mechanism that is dysregulated in many 
polyQ diseases and contributes to their pathology. Previous studies have shown that ATXN3 
is involved in transcriptional regulation processes by binding to specific DNA-motifs and 
chromatin areas of genes, activation of transcriptional co-regulators and formation of histone 
deacetylating complexes, resulting in the repression of target genes. 
The aim of this study was to decipher how ATXN3 might be involved in the transcriptional 
regulation and the cellular response to stress. To that end two patient-specific stem cell 
derived neural stem cell lines were genetically edited by using a CRSIPR/Cas9 KO system, 
specific for the human ATXN3 gene, in order to generate isogenic cell lines, which only differ 
in their state of ATXN3. For each patient foster line, three KO cell lines emerged: one total 
knock-out (KO) of ATXN3 and two hemizygous cell lines expressing the expanded 
(ATXN3_exp) or non-expanded allele (ATXN3_non-exp), respectively.  
This approach enables to search for differentially expressed genes, which might be attributed 
to the expanded and non-expanded allele or a complete KO of ATXN3 within an isogenic 
genetic background. 
Possible candidate genes, which are differentially expressed between the isogenic cell lines, 
were to be analyzed regarding their physiological interactions with ATXN3, functional 
consequences for the generated cell line and an underlying mechanism of this interaction.  
 
 
 
 
-Materials- 
_____________________________________________________________________________________________________ 
 20 
2     Materials 
 
 
2.1   Technical equipment 
 
 
Appliance Name Manufacturer Registered office 
Autoclave  D-150 Systec  Wettenberg, Germany 
Balance   BL610  Sartorius Göttingen, Germany 
Balance  LA310S  Sartorius  Göttingen, Germany 
Block heater  Thermomixer  Eppendorf Hamburg, Germany 
Centrifuge 
(cell culture)  
Megafuge 1.0R  Sorvall  Hanau, Germany 
Centrifuge (table 
top) 
5415D Eppendorf  Hamburg, Germany 
Counting chamber  Fuchs-Rosenthal  Faust  Halle, Germany 
Digital camera  C 5050 Zoom  Olympus Optical  Hamburg, Germany 
Nucleofector  Nucleofector 2b  Lonza  Basel, Switzerland 
Fluorescence lamp  HAL100  Carl Zeiss  Jena, Germany 
Fluorescence 
microscope    
Axioskop 2 Carl Zeiss Jena, Germany 
Freezer -80°C  HERAfreeze  Kendro  Hanau, Germany 
Gel electrophoresis 
chamber  
Agagel  Biometra  Göttingen, Germany 
Imaging system  Chemidoc 2000  Bio-Rad München, Germany 
Imaging system  Geldoc EZ  Bio-Rad München, Germany 
Incubator  HERAcell  Kendro  Hanau, Germany 
Inverse light 
microscope   
Axiovert 25 Carl Zeiss Jena, Germany 
LED light source  Colibri 2 Carl Zeiss  Jena, Germany 
Liquid nitrogen store  MVE 611  Chart Industries  Burnsville, USA 
Microscope   Axiovert 40 CFL  Carl Zeiss Jena, Germany 
Microscope   Axiovert 200M Carl Zeiss  Jena,Germany 
Microscope   Axio Imager Z1 Carl Zeiss  Jena,Germany 
Microscope   DMI6000 B Leica Microsystems Wetzlar, Germany 
Microscope camera  Axiocam MRM  Carl Zeiss  Jena, Germany 
Micro- 
Spectrophotometer  
Nanodrop ND-1000  Thermo Fisher 
Scientific  
Wilmington, USA 
Micropipettes  Labmate L2-L1000 Labmate  Langenfeld, Germany 
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Appliance Name Manufacturer Registered office 
Multilabel reader EnVision 2104 Perkin Elmer Rodgau, Germany 
PAGE/Blot 
equipment  
Mini-Protean 3 Bio-Rad  München, Germany 
PCR cycler  T3000 Termocycler  Biometra Göttingen, Germany 
pH-meter   CG840 Schott  Mainz, Germany 
Pipette-boy  Accu-Jet  Brand  Wertheim, Germany 
Platereader Infinite® 200 PRO Tecan Männedorf, 
Switzerland 
Power supply for 
electrophoresis 
Standard Power 
Pack P25  
Biometra Göttingen, Germany 
Real-time qPCR 
machine 
Mastercycler 
realplex 
Eppendorf Hamburg, Germany 
Refrigerators 
4°C /-20°C  
G 2013 Comfort  Liebherr  Lindau, Germany 
Secure horizontal 
flow hood   
HERAsecure Kendro  Hanau, Germany 
Shaker   Bühler KS15 Johanna Otto  Hechingen, Germany 
Sterile laminar flow 
hood 
HERAsafe  Kendro  Hanau, Germany 
Stereo microscope  STEMI 2000-C  Carl Zeiss  Göttingen, Germany 
Table centrifuge  Centrifuge 5415R  Eppendorf  Hamburg, Germany 
Thermocycler  T3 Thermocycler  Biometra  Göttingen, Germany 
Ultracentrifuge Sorvall Discovery 90 SE Hanau, Germany 
Vacuum pump  Vacuubrand  Brand  Wertheim, Germany 
Vortexer   Vortex Genie 2 Scientific Industries  New York, USA 
Water bath   
 
1008  GFL Burgwedel, 
Germany 
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2.2 Cell culture and molecular biology consumables 
 
 
Consumables Manufacturer Registered Office 
6-well culture dishes Corning Corning, USA 
12-well culture dishes Corning Corning, USA 
24-well culture dishes Corning Corning, USA 
96-well culture dishes Corning Corning, USA 
Cell Strainer 40 μm Nylon  Corning Corning, USA 
Coverslips Menzel Gläser Braunschweig, Germany 
Cryovials 1 ml  Nunc  Wiesbaden, Germany 
Cryovials 1.8 ml  Nunc  Wiesbaden, Germany 
Blotting membrane, 
nitrocellulose 
Sigma-Aldrich  Deisenhofen, Germany 
PCR strip tubes 0.2 ml  peqLab  Erlangen, Germany 
Petri dishes  10 cm  PAA  Pasching, Austria 
Serological pipettes 1 ml   Sarstedt Nümbrecht, Germany 
Serological pipettes 2ml  Sarstedt Nümbrecht, Germany 
Serological pipettes 5ml  Costar, Corning Corning, USA 
Serological pipettes 10ml  Greiner Bio-One  Kremsmünster, Austria 
Serological pipettes 25ml  Costar, Corning Corning, USA 
Syringes 50 ml   BD Biosciences Heidelberg, Germany 
Syringe fier 0.2 μm   PALL Dreieich, Germany 
TC dishes  3.5 cm  FALCON, Corning Corning, USA 
TC dishes  6 cm  FALCON, Corning Corning, USA 
TC dishes  10 cm  FALCON, Corning Corning, USA 
Tubes 0.5 ml  Axygen, Corning Corning, USA 
Tubes 1.5 ml  Axygen, CorningBio-One  Corning, USA 
Tubes 2 ml Axygen, CorningBio-One  Corning, USA, Germany 
Tubes 15 ml  FALCON, Corning Corning, USA 
Tubes 50 ml  FALCON, Corning Corning, USA 
Whatman® Filter paper GE Healthcare Little Chalfont, UK 
qPCR plates 4titude Wotton, UK 
qPCR seals 4titude Wotton, UK 
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2.3 Chemicals 
 
Chemicals  Manufacturer  Registered office 
2-Mercaptoethanol  Invitrogen  Karlsruhe, Germany 
30% Bis/Acrylamide  Carl Roth  Karlsruhe, Germany 
Agar  Sigma-Aldrich  Deisenhofen, Germany 
Agarose  PeqLab  Erlangen, Germany 
Ampiciline  Sigma-Aldrich  Deisenhofen, Germany 
Ascorbic acid (L-) Sigma-Aldrich  Deisenhofen, Germany 
Ammonium persulfate Sigma-Aldrich  Deisenhofen, Germany 
Azide  Sigma-Aldrich  Deisenhofen, Germany 
B-27 supplement  Gibco by Life Technologies  Waltham, USA 
Bromphenol blue Sigma-Aldrich  Deisenhofen, Germany 
BSA solution (7.5%)  Sigma-Aldrich  Deisenhofen, Germany 
CaCl2 Sigma Aldrich  Deisenhofen, Germany 
CdCl2 Sigma-Aldrich  Deisenhofen, Germany 
Chloroform  Carl Roth  Karlsruhe, Germany 
Chloroquin  Sigma Aldrich  Deisenhofen, Germany 
complete, mini, EDTA free Roche Diagnostics Mannheim, Germany 
Cycloheximide Sigma Aldrich  Deisenhofen, Germany 
DAPI Sigma Aldrich Deisenhofen, Germany 
DAPT Axon Medchem Groningen, The Netherlands 
DMEM Gibco by Life Technologies  Waltham, USA 
DMEM/F12 (1:1)  Gibco by Life Technologies  Waltham, USA 
DMSO Sigma Aldrich Deisenhofen, Germany 
DNA ladder (100bp/1kbp)  PeqLab  Erlangen, Germany 
dNTPs  PeqLab  Erlangen, Germany 
Doxycycline Sigma Aldrich Deisenhofen, Germany 
EDTA Sigma Aldrich Deisenhofen, Germany 
EGF R&D Systems Minneapolis, USA 
Ethanol  Sigma Aldrich Deisenhofen, Germany 
Ethidium bromide  Sigma-Aldrich  Deisenhofen, Germany 
FCS  Invitrogen  Karlsruhe, Germany 
FGF2 R&D Systems Minneapolis, USA 
G418 solution  Carl Roth  Karlsruhe, Germany 
Geltrex Gibco by Life Technologies  Waltham, USA 
Glucose  Sigma-Aldrich  Deisenhofen, Germany 
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Chemicals  Manufacturer  Registered office 
L-Glutamate Sigma-Aldrich  Deisenhofen, Germany 
Glycerol  Sigma-Aldrich  Deisenhofen, Germany 
Glycin Sigma-Aldrich  Deisenhofen, Germany 
H2O2 Sigma-Aldrich  Deisenhofen, Germany 
HCl  Sigma Aldrich  Deisenhofen, Germany 
Isopropanol  Sigma Aldrich  Deisenhofen, Germany 
Laminin  Thermo Fisher Scientific Waltham, USA 
LB-Medium powder  Carl Roth  Karlsruhe, Germany 
L-glutamine (100x) Gibco by Life Technologies  Karlsruhe, Germany 
2-Mercaptoethanol Invitrogen  Karlsruhe, Germany 
Methanol ROTIPURAN Carl Roth  Karlsruhe, Germany 
Mowiol  Carl Roth  Karlsruhe, Germany 
Myo-Inositol  Sigma-Aldrich  Deisenhofen, Germany 
N2 supplement (100x)  Gibco by Life Technologies  Karlsruhe, Germany 
Neurobasal medium  Gibco by Life Technologies  Karlsruhe, Germany 
N,N-Dimethylformamide Sigma-Aldrich  Schnelldorf, Germany 
Non-essential amino acids  
(100x) 
Gibco by Life Technologies  Karlsruhe, Germany 
DPBS  Gibco by Life Technologies  Waltham, USA 
PFA  Sigma  Aldrich Deisenhofen, Germany 
Penicillin-Streptomycin Gibco by Life Technologies  Karlsruhe, Germany 
Poly-L-ornithine  Sigma-Aldrich  Deisenhofen, Germany 
Puromycin PAA Pasching, Austria 
p-Coumaric acid Sigma-Aldrich  Deisenhofen, Germany 
Polyvinylalcohol Sigma-Aldrich  Deisenhofen, Germany 
Powdered milk Carl Roth  Karlsruhe, Germany 
Pyocyanin Sigma-Aldrich Schnelldorf, Germany 
Rotenone-Calbiochem Merck Darmstadt, Germany 
SDS  Sigma-Aldrich  Deisenhofen, Germany 
Sodium pyruvate (100x) Invitrogen  Karlsruhe, Germany 
TEMED  Sigma Aldrich  Deisenhofen, Germany 
TriFast peqGOLD PeqLab  Erlangen, Germany 
Tris  Sigma Aldrich  Deisenhofen, Germany 
Triton-X-100  Sigma Aldrich  Deisenhofen, Germany 
Trypane Blue  Invitrogen  Karlsruhe, Germany 
Trypsin inhibitor (TI)  Gibco by Life Technologies  Waltham, USA 
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Chemicals  Manufacturer  Registered office 
Trypsin-EDTA (10x)  Gibco by Life Technologies  Waltham, USA 
ZnCl2 Sigma-Aldrich  Deisenhofen, Germany 
 
 
2.4 Cell culture 
 
 
2.4.1 Cell culture media 
 
All cell culture reagents were prepared under sterile conditions and stored at 4°C; % = v/v. 
 
MEF (mouse embryonic feeder)  
86%        DMEM-high-glucose 
10%           FCS 
1x             Sodium pyruvate 
1x          L-Glutamine 
1x       Non-essential amino acids 
1x       Pen / Strep 
 
 
Neural stem cell (N2) medium 
98%     DMEM/F12 
1x           N2 Supplement 
1x          Penicillin/Streptomycin 
0.4% D-Glucose solution 
 
 
Basic small molecule medium 
98,3%     DMEM/F12 
0.5x           N2 Supplement 
1x          Penicillin/Streptomycin 
0.2% D-Glucose solution 
 
 
Neural stem cell freezing medium 
70%        KnockOut™ Serum Replacement 
20%       CytocoonTM Buffer II 
10%       DMSO 
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Neuronal generation (NGMC) medium  
96.8%     DMEM/F12 
0.5x       N2 Supplement 
0.5x        B27 supplement 
1x          Non-essential amino acids 
1x        Penicillin/Streptomycin 
0.2% D-Glucose  
 
 
FCS-based freezing medium 
90%        FCS, heat inactivated 
10%       DMSO 
 
 
 
2.4.2 Cell culture solutions 
 
1xTrypsin/EDTA (TE) 
90%       PBS 
10%       Trypsin/EDTA (TE) 10x 
 
 
Trypsin inhibitor (TI)  
100%     PBS 
0.25 mg/ml Trypsin inhibitor (>700 units/mg) mixed in PBS, sterile-filtered and 
stored at 4°C 
 
 
Poly-L-ornithine (PO) 
100%        H2O 
1.5 mg/ml  Poly-L-ornithine (PO) mixed, sterile-filtered and stored at 4°C 
 
 
Laminin (Ln) coating solution 
100%     H2O 
1 μg/ml Laminin (Ln) in PBS 
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Geltrex (GT) LDEV-free coating solution 
98%      DMEM/F12 
2%         Geltrex 
 
 
Cyto buffer for cell freezing 
43,25g Myo-Inositol (in 800ml distilled water) 
200ml PBS 
5g Polyvinylalcohol 
Add Polyvinylalcohol in small portions, stir continuously. The mixture was sterile-filtered and 
stored at 4°C 
 
 
Glucose solution (0,4g/ml) 
100%     Ampuwa H2O 
0.4 g/ml L-glucose mixed in Ampuwa H2O , sterile-filtered and stored at 4°C 
 
 
Balanced salt solution (BSS) for L-glutamate treatment  
25mM  Tris,  
120mM  NaCl 
15mM  D-glucose 
5.4mM  KCl 
1.8mM  CaCl2 
0.8mM  MgCl2 
H2O was added to 500 ml, the pH was adjusted to 7.4, the mixture was sterile-filtered and 
stored at 4°C 
 
 
2x HBS buffer  
8 g  NaCl 
0.38 g  KCl 
0.1 g  Na2HPO4 
5 g  Hepes 
1 g  Glucose 
H2O was added to 500 ml, the pH was adjusted to 7.05, the mixture was sterile-filtered and 
stored at -20°C 
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2.4.3 Cell culture additives 
 
Reagent                                 Concentration                      Solvent 
B27 supplement 50x supplement mix 
bDNF 10 µg/ml PBS + 0.1% BSA 
CHIR99021 10 mM DMSO 
Chloroquin 50 mM H2O 
DAPT 25 mM DMSO/Ethanol (1:5) 
DNase 10 mg/ml H2O 
Doxycycline 1 mg/ml H2O 
EGF                                       10 µg/ml PBS 
FGF2                                     10 µg/ml PBS + 0.1% BSA 
G418                                      50 mg/ml H2O 
gDNF 10 µg/ml PBS + 0.1% BSA 
L-Ascorbic acid 200 mM H2O 
N2 supplement 100x supplement  
Purmorphamine (PMA) 5 mM DMSO 
Puromycin 1 mg/ml H2O 
Y-27632 (Rho-Kinase-Inhibitor) 5 mM H2O 
 
 
2.4.4 Cell lines 
 
Cell line  Source 
E. coli DH5a   Invitrogen, Deisenhofen, Germany 
HEK-293FT Leiden, Netherlands, Dr. Alex Van der Eb 
iPS cell line MJD 1  Bonn, Germany  
iPS cell line MJD 2 Bonn, Germany  
iPS cell line MJD 3 control Bonn, Germany (Koch et al., 2011) 
 
 
 
2.5 Molecular biology 
. 
 
2.5.1 Reagents 
 
PFA fixation solution (4%) 
40 g  PFA 
1000 ml  H2O 
The solution was heated until PFA dissolved completely, pH adjusted to 7.4 and sterile 
filtered. 
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6x DNA loading buffer  
2 ml  EDTA (0.5M; pH 8.5) 
6 g  Sucrose 
0,2 ml  2% Bromphenol-blue-solution 
0,2 ml  2% Xylene-cyanol-solution 
0,2 g  Ficoll 
3,8 ml  Aqua bidest. 
The solution was mixed well, prepared in 1 ml aliquots and stored at 4°C 
 
 
Immuno-blocking solution 
89.9%    PBS 
10%     FCS 
0.1%      Triton X100 (only for intracellular epitopes) 
 
 
Moviol / DABCO  
12 ml  Tris solution (0.2 M; pH 8.5) 
6 ml  H2O 
6 g  Glycerol 
2.6 g  Moviol 
0.1 g  DABCO 
 
 
50x Tris-acetate-EDTA-buffer (TAE) 
242 g  Tris 
100 ml  EDTA solution (0.5M; pH 8.5) 
57.1 ml  Water-free acetic acid (100%) 
add H2O to 1000ml 
 
 
SDS-PAGE separation gel buffer 
99.6%  Tris solution (1.5M; pH 8.8) 
0.4%  SDS 
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SDS-PAGE stacking gel buffer  
99.6%  Tris solution (1.5M; pH 6.8) 
0.4%  SDS 
 
 
SDS-PAGE buffer 10x    
30 g  Tris 
144 g  Glycin 
add H2O to 1000 ml (pH 8.0) 
For running buffer add 1% SDS to 1x SDS-PAGE buffer 
For blotting buffer add 20% Methanol to 1x SDS-PAGE bufffer 
 
 
Protein loading buffer 
75.75%     Tris solution (0.1 M; pH 6.8) 
20%         Glycerol 
4%            SDS 
0.25%       Bromphenol blue 
 
 
10x TBS  
80g     NaCl 
2g       KCl 
30g    TrisBase 
add    H2O to 1000 ml, pH 7.4 
For 1x TBST dilute 10x TBS 1:10 with H2O and add 1% Tween-20 
 
 
Lysis buffer 
2.5 ml Tris HCl (1 M) 
5 ml NaCl (1.5 M) 
2.5 ml EDTA (0.5 M) 
TritonTM X-100 100 µl 
Add to 50 ml aqua bidest. 
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TE4-buffer  
1.58 g  Tris-HCl 
0.29 g  EDTA 
add H2O to 1000 ml 
Adjust pH to 8 with solid NaOH 
 
Enhanced chemiluminescence (ECL) solution 
4.5 ml H2O 
0.5 ml Tris HCl (1 M) 
50 µl Luminol 
20 µl p-coumaric acid 
1.5 µl H2O2 (30%) 
 
PCR master mix (10 ml) 
1 ml 10x reaction buffer 
600 µl MgCl2 (50 mM) 
40 µl each dNTPs 
8.24 ml Ampuwa H2O 
 
 
qPCR master mix (5 ml) 
2000 µl GoTaq® Flix buffer 
1000 µl MgCl2 (25 mM) 
20 µl each dNTPs 
7.5 µl 1000x SYBR-green 
1 µl Fluorescin 
400 µl DMSO 
1511.5 µl Ampuwa H2O 
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2.5.2 Enzymes 
 
Enzyme name Manufacturer Registered office 
Alkaline Phosphatase, Shrimp  Roche Diagnostics  Penzberg, Germany 
DNaseI (cell culture) Roche Basel, Switzerland 
DnaseI (molecular biology) Invitrogen Karlsruhe, Germany 
GoTaq G2 Flexi DNA polymerase Promega Mannheim, 
Germany 
Phusion High Fidelity DNA Polymerase  New England Biolabs  Frankfurt, Germany 
T4 DNA Ligase  New England Biolabs  Frankfurt, Germany 
Taq DNA Polymerase, recombinant  Invitrogen  Karlsruhe, Germany 
 
 
 
2.5.3 Plasmids 
 
Plasmid name Source or parent DNA seauence 
pMD2.G Gift from Dider Trono, Lausanne, Switzerland 
psPAX2 Gift from Dider Trono, Lausanne, Switzerland 
pLVX-EtO Modified from pLVX-Tet-ON-Advanced (Clontech) 
pLVXTP Equivalent to pLVX-Tight-Puro (Clontech) 
pChMTFVSV Gift from Oleg Georgiev, Zürich, Switzerland 
pLVXTP-MTF1-VSV Modified from pLVX-Tet-ON-Advanced (Clontech) 
pLVXTP-ATXN3C71 Modified from pLVX-Tet-ON-Advanced (Clontech) 
 
 
 
2.5.4 Restriction endonucleases 
 
Enzyme name Restriction site Manufacturer Registered office 
NotI 5’…GC^GGCCGC…3’ 
3’…CGCCGG^CG…5’ 
New England Biolabs Frankfurt, Germany 
MluI 5’...A^CGCGT...3’ 
3’...TGCGC^A...5’ 
New England Biolabs Frankfurt, Germany 
 
 
 
2.5.5 Bacterial solutions 
 
LB agar  
20 g          LB-Medium powder (Roth) 
15 g            Agar 
H2O was added to 1 l, the mixture was autoclaved and stored at 4 °C 
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LB medium  
40 g      LB-Medium powder (Roth) 
H2O was added to 2 l, the mixture was autoclaved and stored at 4 °C 
 
 
2.5.6 Kits 
 
Name  Producer  Office 
CellTiter-Glo® Luminescent Cell 
Viability Assay 
Promega Mannheim, Germany 
DNeasy Blood & Tissue Kit  Qiagen  Hilden, Germany 
 
iScript cDNA Synthesis Kit  Bio-Rad  München, Germany 
 
NucleofectorTM  Lonza Basel, Switzerland 
peqGOLD Gel Extraction Kit  Peqlab Biotechnologie  Erlangen, Germany 
 
peqGOLD Plasmid Miniprep Kit  Peqlab Biotechnologie  Erlangen, Germany 
 
PierceTM BCA Protein Assay Kit 
 
Thermo Fisher Scientific Rockford, USA 
PureYield Plasmid Maxiprep 
System  
Promega Mannheim, Germany 
RNeasy Kit  Qiagen  Hilden, Germany 
 
ROS-ID Total ROS/ Superoxide 
detection kit 
Enzo Life Scienes Lörrach, Germany 
 
 
2.5.7 Primer 
 
 
Cloning primer* 
Name                                       
 
Primer sequence (5’-3’) 
MTF-1VSV-NotI_F                      ATAATAGC^GGCCGCGCCGCCACCATGGGGGAACACAGTCC 
MTF-1VSV-MluI_R                     CAGTA^CGCGTGCGAGCTCGCAGGATTTGAG 
 
 
Sequencing primer 
Name                                       
 
Primer sequence (5’-3’) 
Seq: Atxn3_1_F GGCTCCAGACAAATAAACATGGA 
Seq: Atxn3_1_R GATCGATCCTGAGCCTCTGA 
Seq: Atxn3_3_F TGAGGAGGATTTGCAGAGGG 
Seq: Atxn3_3_R ACGCATTGTTCCACTTTCCCA 
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qPCR primer 
Name                                       
 
Primer sequence (5’-3’) 
qPCR:MT1A_F                  GCAAAGGGGCATCAGAGAAG 
qPCR:MT1A_R                  TGGGTCAGGGTTGTATGGAA  
qPCR:MT1E_F                  ATCCTCTGGGTCTGGGTTCT 
qPCR:MT1E_R                  GGGAAGAAGGGGAGAGTGAG 
qPCR:MT1G_F                  GCCCTGCTCCCAAGTACAAA 
qPCR:MT1G_R                  AGGGGTCAAGATTGTAGCAAA 
qPCR:MT2A_F                   CCGACTCTAGCCGCCTCTT 
qPCR:MT2A_R                   CAGCAGCTTTTCTTGCAGGA 
qPCR:MTF1_F                   AGACTTTCTCTTCAGCCCCT 
qPCR:MTF1_R                   AACTCTGACACATCCATGGC 
qPCR:SOD2_F                   TGGGGTTGGCTTGGTTTCAA 
qPCR:SOD2_R                   AAGGCCTGTTGTTCCTTGCA 
qPCR:RPLPO_F AGCCCAGAACACTGGTCT 
qPCR:RPLPO_R ACTCAGGATTTCAATGGTGCC 
qPCR:18S_F TTCCTTGGACCGGGGCAAG 
qPCR:18S_R GCCGCATCGCCGGTCGG 
 
 
 
2.5.8 Antibodies 
 
Primary antibody  Dilution  Source 
Atxn3c clone 1H9-2  1:1000  BioLegend 
Atxn3 1C2  1:1000  Millipore 
Beta-III-tubulin 1:2000 Sigma-Aldrich 
Β-actin 1:5000 Millipore 
DACH1 rb 1:100  ProteinTech 
GFAP 1:500  DAKO 
MAP2ab 1:250  Sigma-Aldrich 
Metallothinein [UC1MT] 1:500 Abcam 
Nestin ms 1:600  R&D Systems 
NeuN  1:100  Millipore 
Pax6 rb 1:500 Developmental studies 
hybridoma bank (DSHB) 
PLZF ms 1:50 Merck 
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Primary antibody  Dilution  Source 
Sox2 ms 1:300 R&D Systems 
VSV-G tag 1:1000 Thermo Fisher 
ZO-1 rb 1:100 DSHB 
 
 
 
Secondary antibody  Dilution  Source 
Alexa488 gt-anti-ms  1:1000 Life technologies 
Alexa488 gt-anti-rb 1:1000 Life technologies 
Alexa555gt-anti-ms  1:1000 Life technologies 
Alexa555gt-anti-rb 1:1000 Life technologies 
HRP-gt-anti-ms  1:1000 GE Healthcare Life Sciences 
HRP-gt-anti-rb 1:1000 Thermo Scientific 
ms = mouse; rb = rabbit; gt = goat 
 
 
 
2.6 Software 
 
Name  Application  Producer 
ApE – A plasmid Editor 
v2.0.47  
Cloning strategies  M. Wayne Davis 
 
AxioVision 40 4.5.0.0 Fluorescence microscopy  Carl Zeiss  
ClustalW v1.83  Sequence alignment  EMBL-EBI  
EnrichR Gene analysis Kuleshov et al., 2016 
Excel 2008 Data analysis Microsoft 
Image J 1.42q Quantifications NIH 
Imagelab 5.0 build 18 Western blot documentation Bio Rad 
GenomeStudio 2011 SNP analysis  Illumina 
Microsoft Office 2008  Figures and text processing  Microsoft 
Photoshop CS3  Figures processing  Adobe 
Primer3 v0.4.0  Primer picking  Rozen and Skaletsky 
(2000) 
Prism 5 Data analysis and statistics GraphPad 
Quantity One 4.6.8 Electrophoresis gel 
documentation  
Bio Rad 
 
Word 2008 Writing documents Microsoft 
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3     Methods 
 
 
3.1   Cultivation of human pluripotent stem cell-derived neural stem cells  
 
Small molecule neural precursor cells (smNPCs) were generated from induced pluripotent 
stem cells as previously described (Reinhardt et al., 2013) and cultured on GelTrex-coated 6-
well (Falcon) cell culture plates. Cell expansion medium consisted of DMEM-F12 (Gibco) 
with 1:200 N2 supplement (Invitrogen), 1:200 B27 supplement lacking vitamin A (Gibco), with 
1% penicillin/streptomycin (Gibco), freshly supplemented with 3 µM CHIR 99021, 0.3 µM 
Purmorphamine (PMA), and 100 µM ascorbic acid (AA), with a medium change every day. 
Typically, cells were split 1:4 every 3 or 4 days. For splitting, cells were digested into single 
cells for about 8 minutes at 37°C by using Trypsin-EDTA (Gibco). The same amount Trypsin-
Inhibitor was added to stop the digestion and the mixture was diluted in DMEM (Gibco) for 
centrifugation at 1200x for four minutes. The cell pellet was resuspended in fresh smNPC 
expansion medium and plated on GelTrex-coated cell culture dishes. 
 
 
3.2 Differentiation of neural stem cells into neurons 
 
Small molecule neural precursor cells are multipotent stem cells that constantly retain their 
capability to generate defined cultures of neurons and glial cells over a certain period of time, 
making them a useful neural progenitor population. Before final differentiation, medium of 
smNPCs was exchanged to DMEM/F12, containing EGF and FGF2, for 24 h (Koch et al., 
2009). The generated long-term neuroepithelial-like cells (ltNESc) were transferred to geltrex 
(GT)-coated cell culture dishes and differentiated to neuronal cultures by withdrawing of 
growth factors from the culture medium upon reaching confluence. Culture medium was 
exchanged every second day. Neuronal enrichment was achieved by adding 10 μM DAPT 
(Sigma). 
 
 
3.3 Generation of isogenic induced pluripotent stem cell-derived neuronal cultures via 
CRISPR/Cas editing     
 
In order to generate isogenic iPSC-derived neuronal cultures expressing either the KO or the 
normal ATXN-3 gene, a CRISPR/Cas editing system (Santa Cruz; Figure 3.1) was applied 
via nucleofection of smNPCs. The CRISPR/Cas system consists of two parts: three 
CRISPR/Cas9 Knockout (KO) plasmids each encoding the Cas9 nuclease and a target-
specific 20 nt guide RNA (sc-417498A1: 5’…ATCCTCAATTGCACATCAG...3’; sc-417498A2: 
5’…TCAACAGTCCAGAGTATCAG…3’; sc-417498A3: 5’…ATCCTGAGCCTCTGATACTC… 
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3’) and a homology-directed repair (HDR) plasmid which incorporates, when co-nucleofeted 
with the CRISPR/ Cas9 KO plasmid, a puromycin resistance gene for selection of cells 
where Cas9-induced DNA cleavage has occurred. Also a total number of three of the HDR 
plasmids was used, each containing a HDR template corresponding to the cut sites 
generated by the corresponding CRISPR/Cas9 KO plasmids providing a specific DNA repair 
template for a double strand break.  
 
 
3.3.1  Nucleofection of ATXN3-CRISPR/Cas KO system into SCA3 patient-derived 
neural stem cells 
 
2.5 x 106 cells of two SCA3 patient-derived iPSc-derived smNPCs cell lines were used for 
the nucleofection with the ATXN3-CRISPR construct, according to the manufacturer’s 
protocol (Lonza). Briefly, cells were washed with PBS, harvested by using Trypsin-EDTA and 
centrifuged for 4 min. at 1200x. Then, cells were counted and 2.5 x 106 cells of the counted 
cells were centrifuged a second time. The pellet was cleared from any residual medium and 
resuspended in 100 µl of a Nucleofector® solution. Afterwards, 2 µg of the ATXN3-
CRISPR/Cas9 DNA were added to the nucelofector-cell suspension.  The mixture was 
transferred to a cuvette, placed into a holder of the Nucleofector and the recommended 
program was started. Finally, the nucelofected cell suspension was resuspended in 500 μl of 
the pre-warmed culture medium and transferred into the medium containing six-well plates. 
 
 
3.3.2  Cultivation and screening of nucleofected ATXN3 /CRISPR clones 
 
48h after the nucleofection with the ATXN3 /CRISPR construct, smNPCs were selected in 
culture medium containing 1 µg/µl puromycin for two days. Following the removal of 
puromycin form the culture medium the surviving cells were cultured for three weeks until 
resistant colonies emerged. As soon as colonies began to form spherical bulges, they were 
picked with a 100 μl micropipette by scratching and soaking, and then plated onto 96 well-
plates. Within a few days the clones reached confluency and were dissociated with trypsin-
EDTA, separated and plated onto a 24-well and expanded. As soon as enough cells of a 
clone were present to secure the propagation, one well of a six-well was harvested in lysis 
buffer and a western blot analysis was done for screening purposes. 
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3.4  SDS –PAGE and western immuno blotting 
 
For SDS-PAGE, cells were harvested and lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 
2% SDS, 25 mM EDTA, 1x Roche cOmplete mini protease inhibitor) for 1h at 4°C. Lysates 
were clarified by centrifugation (10.000 rcf; 10 min) boiled for 5 minutes at 95°C and loaded 
onto 12% SDS-PAGE gels containing resolving- and stacking gels. Gels were casted using 
30% Acrylamid/Bisacrylamid (37.5:1; Carl Roth), TEMED, 10% APS, 10% SDS and the 
respective gel buffers. Loaded protein lysates were electrophoresed at 100V in MINI-Protean 
chambers (Biorad) and transferred onto nitrocellulose membranes by using a Trans-Blot® 
Turbo™ Transfer System (0.5A, 15V, 1h; Biorad). 
Following the blotting, membranes were blocked with 5% milk powder (Carl Roth) in TBST 
for 1h and incubated with the respective primary antibody (listed) over-night at 4°C. Washed 
membranes were incubated with an HRP-linked secondary antibody (1 h) and imaged with 
the ChemiDoc™ XRS+ System. Quantification of signals from sub-saturated blots was done 
using ImageJ. Protein signal was normalized to the loading control pan-actin. 
 
 
3.5  SNP analysis and sequencing 
 
Genomic DNA was prepared using the DNeasy Blood & Tissue Kit (Qiagen). Whole-genome 
single nucleotide polymorphism (SNP) genotyping was performed at the Institute of Human 
Genetics at the University of Bonn. Genomic DNA at a concentration of 50 ng/μl in TE4 
buffer was used for whole-genome amplification. Afterwards, the amplified DNA was 
fragmented and hybridized to sequence-specific oligomers bound to beads on an Illumina 
OmniExpressExome v1.2 chip. Data were analyzed using Illumina GenomeStudio V2011.1 
(Illumina). Genotypes were produced using the genotyping module of GenomeStudio and 
copy number variation (CNV) analysis was performed. Furthermore, B-allele frequencies and 
log R ratios were visualized. 
 
 
3.6  RNA extraction with Trifast 
 
Cells were lysed with 1ml Trifast directly in culture plates, homogenised and collected in a 
1.5ml tube. For the following phase separation, 200µl chlorophorm were added to the probes 
and tubes were shaked for 30 seconds at RT. Afterwards, the mixture was incubated for 7-15 
minutes at RT and centrifuged at 12,000g for 10 minutes. Following centrifugation, three 
phases were visible within the tube. The top phase, containing RNA, was carefully 
transferred to a fresh tube without being contaminated with the other phases. For the next 
step, the RNA precipitation, 500 µl isopropanol were added to the tube, the mixture was 
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shaked and incubated on ice for up to four hours. After the following centrifugation step 
(12,000g, 10 min., 4°C), a gel-like RNA-precipitate was visible. The pellet was twice washed 
with 800 µl of 75 % EtOH-Diethyl pyrocarbonate (DEPC) water and centrifuged as before. 
The remaining ethanol was air dried for 30-60 min. Last, the pellet was redissolved with 20 µl 
of DEPC water and shaked at RT for 30 minutes.  
 
 
3.6.1 RNA purification with DNaseI 
 
For RNA purification DNaseI (Invitrogen) was used to digest single- and double stranded 
DNA in extracted RNA samples. 2.5 µl of 10x DNaseI reaction buffer and 2.5 µl of DNaseI 
were added to each RNA sample and incubated for 15 min at RT. Next, in order to inactivate 
the DNaseI, 2.5 µl EDTA (25mM) were added and the mixture was incubated for 10 min. at 
65°C. Following the RNA purification, the RNA concentration was measured using a micro- 
spectrophotometer (Nanodrop ND-1000 ). 
 
 
3.7      L-glutamate treatment of neuronal cultures 
 
Three clones of each group were cultured in 3.5-cm dishes for four weeks in differentiation 
medium until neuronal cultures were fully mature. Cells were washed two times with 2 ml 
BSS (balanced salt solution) containing 25 mM Tris, 120 mM NaCl, 15 mM glucose, 5.4 mM 
KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, pH 7.4 and treated with 100 µM L-glutamate (Sigma, no. 
G8415) in BSS for 30 min. Afterwards, cells were washed again two times and kept in 
differentiation medium for another 30 min (recovery phase), followed by two additional wash 
steps with BSS. Cells were exposed to a second excitatory stimulus by adding 100 µM L-
glutamate for 30 minutes. Afterwards, neurons were cultured for 24 h at 37°C. On the next 
day, cells were harvested in TriFastTM for RNA extraction. 
 
 
3.8 Gene expression analysis 
 
For gene-expression microarrays, mRNA of neuronal cultures from three clones of each 
group in biological duplicates (n=6) under normal culture conditions and following exposure 
of the cultures to 100 µM L-glutamate, were isolated using TriFastTM. Samples were analyzed 
on the HumanHT-12 v4 Expression BeadChip (Illumina). RNA samples were handled 
following Illumina's laboratory guidelines. Data processing was performed using 
GenomeStudio V2010.3 Gene Expression Module (V1.8). For data normalization raw-probe 
and gene-level data were extracted without background subtraction, selecting those probes 
with a detection P value of <0.5 as computed by GenomeStudio and the resulting probe 
intensity values were quantile-normalized across the data set. 
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3.9 Quantitative  RT-PCR 
 
Total RNA was obtained from cultured cells by using a TriFast-chloroform-exraction and 
mRNA transcripts were incubated with DnaseI. For the reverse transcription, 1 µg of RNA 
was used and reversely transcribed into cDNA by using the iScript cDNA Synthesis Kit 
(BioRAD) in accordance with the manufacturer’s protocol. Quantitative RT-PCR reactions 
were performed in triplicates on a Biorad-iCycler realplex mastercycler using the Promega 
GoTaq G2 Flexi DNA polymerase and the SYBR-green detection method.  PCR products 
were assessed by dissociation curve analysis (iCycler iQ™ Real-Time PCR Detection 
System) and data were normalized to RPLPO or 18S mRNA expression levels (RT-PCR 
primers listed) to ensure comparable expression levels of genes. Analyses were done using 
the ΔΔCt-value method. 
PCR products were separated on a 2% agarose gel in TAE buffer containing 1:10000 
ethidium bromide and visualized in a UV-light gel documentation system. 
 
Step Temperature Time 
Initial denaturation 95 °C 2 minutes 
40 cycles:   
Denaturation 95 °C 15 seconds 
Annealing 60 °C 15 seconds 
Elongation 72°C 20 seconds 
 
 
3.10  Immunocytochemical analysis 
 
Cells were fixed in 4% PFA for 15 min at room temperature, washed twice with PBS and 
blocked with 10% FCS and 0.1% Triton-X-100 in PBS for one hour at room temperature. 
Afterwards, primary antibodies (listed) were applied overnight at 4°C in blocking solution. 
Cells were washed twice with PBS before secondary antibodies (listed) were applied for 1 h 
at room temperature. 
Cell nuclei were counterstained with DAPI and finally cells were rinsed with PBS, mounted 
with Moviol and covered with a glass coverslip. 
 
 
3.11 Assessment of cell viability  
 
 
Cells from the different isogenic conditions were incubated on 10 cm-dishes under DAPT 
treatment for four days at 37°C and 5% CO2 to initiate differentiation of an increased number 
of neurons. Afterwards, the obtained premature neurons were plated at 40.000 cells per well 
in 96-well microtiter plates and differentiated into mature neurons for four weeks. Following 
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differentiation, the compounds Rotenone [5 µM, 25 µM and 50 µM], CdCl2 [10 µM, 25 µM 
and 50 µM], ZnCl2 [100 µM, 150 µM and 200 µM] and L-glutamate [2 mM, 5 mM, 7.5 mM and 
10 mM] were added to wells, respectively and cultures were incubated for additional 48 
hours. Cell viability was evaluated by using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega). The substrate was prepared using the manufacturer’s instructions and 25 
µL of the CellTiter-Glo cell lysis reagent was added to each well. For cell lysis and 
equilibration of signal, 96-well plates were mixed on a compact shaker (Bühler) for 30 min at 
RT. Subsequently, the contents of the device were transferred to a 96-well clear bottom 
black plate and luminescence was measured on an EnVision Multilabel Plate Reader (Perkin 
Elmer). The assay generates a luminescence signal during a luciferase reaction. Since the 
luciferase reaction requires ATP, the luminescence produced is proportional to the amount of 
ATP present, an indicator of cellular metabolic activity. The relative cell survival rate [%] was 
calculated by comparing the rotenone-treated cells with a DMSO control and the Cd-, Zn- 
and L-glutamate- treated cells with a H2O control. 
 
 
 
3.12  Superoxide and total ROS induction 
 
For measuring total cellular levels of ROS and superoxide, the total ROS/Superoxide 
detection kit was used. One-week-old neurons were transferred to GT-coated 96 well plates 
and differentiated for another three weeks. On the day of the experiment, differentiation 
medium was replaced by DMEM/F12 (without B27) and after four hours, cells were treated 
with pyocyanin [150, 300 and 500 µM] for 30 min., respectively. Afterwards, the detection kit 
was used according to the manufacturers instructions (ENZO). Recording of superoxide 
(Ex=550nm, Em=610nm) and total ROS (Ex=488, Em=520) fluorescence signals was 
performed using a plate reader (Tecan Group Ltd.). 
 
 
3.13  Design of lentiviral vectors 
 
 
As a conditional overexpression system, a modified variant of the Lenti-XTM Tet-On 
Advanced system (Clonetech) was used (the CMV promoter had been exchanged by an 
EF1α promoter in the pLVX-Tet-On plasmid to regulate expression of rtTAAdv. protein).  
For constant overexpression of MTF-1 with a VSV taq (MTF-1_VSV) and a truncated form of 
ATXN3 (ATXN3_C71), the pLVX-Tight-Puro vector was used. The cDNA for both genes was 
amplified by PCR (cloning primers listed). MTF-1 was amplified from the plasmid pChMTF-
1_VSV (Gift from Oleg Georgiev, Switzerland). PCR products were separated by agarose gel 
electrophoresis, extracted by manual excision of the respective band under UV light, isolated 
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by gel purification (peqGOLD™ Gel Extraction Kit, Peqlab), digested using appropriate 
restriction enzymes (listed) and ligated (T4 DNA Ligase, NEB) into linearized, 
dephosphorylated (FastAPTM, Fermentas) pLVX-Tight-Puro vector under control of the 
inducible TREtight promoter, resulting in pLVXTP-gene vectors (listed). 
 
 
 
3.14  Production and concentration of lentiviral particles 
 
For production of lentiviral particles, HEK293-FT cells were grown on a polyornithine- coated 
15 cm dish in MEF medium. 70-80% confluent cells were co-transfected with lentiviral 
plasmids of the second generation by calcium-phosphate precipitation as described 
previously (Kutner et al, 2009). Briefly, 7 μg of the envelope plasmid pMD2.G and 15 μg of 
the packaging plasmid psPAX2 together with 30 μg of the transfer vector were mixed, and 
H2O was added to a final volume of 1400 μl. 178 μl of CaCl2 solution (2,5 M) was added, 
and the solution was slowly mixed with 1400 μl of 2xHBS buffer (pH=7,05). The suspension 
was incubated for 40 min at RT and added drop wise to the 293FT cells that were pre-
incubated with with chloroquin (25 μM, 5 min, 37°C in MEF). The next day, transfected cells 
were washed with PBS (37°C) once. The supernatants of day two and three were pooled, 
filtered through a 0,45 μm filter and concentrated by centrifugation (44000 g; 4°C, 2h). Viral 
particles were resuspended in virus freezing medium and stored in aliquots at -80°C. 
 
 
 
3.15  Lentiviral transgenesis of pluripotent stem cell-derived neural stem cells 
 
To generate an smNP cell line for conditional overexpression of MTF-1_VSV and 
ATXN3_C71, smNP cells from SCA3 patient-derived iPS cell lines were first transduced with 
lentiviral particles containing the EF1α regulated rtTAAdv protein. 48 hours after 
transduction, cells were chemoselected with G418 (100 μg / ml, PAA) for four days. Next, 
cells were transduced with the respective pLVXTP-gene virus to obtain inducible cell lines for 
the respective gene. Cell lines were continuously cultured in G418 and puromycin containing 
culture media (Puromycin: 1 μg / ml, PAA; G418: 100 μg / ml, PAA). 
 
 
 
3.16 Cycloheximide chase 
 
Cells were differentiated into neurons for five weeks. On the first day of experiment medium 
was removed and 200 µg/ml cycloheximide (dissolved in 100% EtOH) in fresh medium was 
added to the cells. Cells with t=0 were collected immediately and stored in -80° C. Remaining 
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cells were chased for t=4, 12, 24 and 48 h and lysates were collected at each time point. 
After all lysates were collected, they were centrifuged at 12.000 rpm at 4° C for 30 min and 
protein concentrations were measured. 50 µg of protein were loaded on a 12 % gel and 
western immuno blot was performed as described before (anti-VSV antibody with dilution 
1:1000 was used to detect the MTF1_VSV signal and β-actin was used with a dilution 
1:10.000 as a control). 
 
 
3.17 Statistical analysis 
 
Quantitative data of each cell line was generated in biological duplicates and ≥3 technical 
replicates unless otherwise mentioned. All results show means ±standard deviation (SD). 
Means and SD were computed using Microsoft Excel 2008 and GraphPad Prism6 software. 
A student’s t-test was performed to determine whether a significant difference between 
groups exits. A two-way ANOVA was performed to determine whether a significant difference 
exists between groups when influenced by two independent variables. Multiple pairwise 
comparisons of means were performed by Tukey’s posthoc test (*p <0.05; **p<0.01; ***p 
<0.001; ****p <0.0001).  
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4     Results 
 
Modeling protein functions in iPSC-derived in vitro cultures is challenging in regard to high 
variations in differentiation protocols and genetic variations between cell lines. For instance, 
when using a stem cell based model system, it has to be considered that in contrast to 
mouse models, being inbred strains, humans are genetically diverse. DNA sequencing 
analysis indicates that every time human DNA is passed from one generation to the next it 
accumulates 100–500 new mutations (Besenbacher et al., 2015; Kondrashov et al., 2002; 
Xue et al., 2009). Thus, in an ideal case, isogenic cultures are applied where cell lines differ 
only in the gene of interest. In addition, stable intermediates generated during the lengthy 
differentiation process represent an attractive alternative cellular source.  
One example for such an intermediate cell population are small molecule neural precursor 
cells (smNPCs), which fulfill two major requirements: reproducibility and comparability 
between single experiments and different stem cell lines. They represent a robust 
intermediate stem cell population between pluripotent stem cells and differentiated neuronal 
cultures that can be generated from either control or patient-derived iPS cell lines (Reinhardt 
et al., 2013). These cells were applied to address how an expansion and/or loss of the 
protein Ataxin 3, in accordance with the loss of function hypothesis, might affect gene 
expression in human isogenic iPSC SCA3 patient-derived neuronal cultures. Due to their 
stability and clonal growth in culture, smNPCs are also amenable to genetic manipulations. 
Thus, CRISPR-Cas9-based gene editing could be used to genetically manipulate smNPCs in 
order to generate isogenic iPSC-derived neural stem cell lines expressing either the non-
expanded or the expanded allele of ATXN3. In addition, and as a control, neural stem cells 
with a complete knockout of the ATXN3 gene were generated. 
 
 
4.1 CRISPR/Cas9 genomic editing is suitable for the generation of stable stem cell-
derived neural stem cell lines 
 
In order to rule out any influences due to the human genetic diversity, isogenic iPSC-derived 
neural stem cell lines were generated, using CRISPR/Cas9-mediated gene editing. The 
CRISPR/Cas system consists of two parts: three CRISPR/Cas9 Knockout (KO) plasmids 
each encoding the Cas9 nuclease and a target-specific 20 nt guide RNA for ATXN3 and a 
homology-directed repair (HDR) plasmid which incorporates, when co-nucleofeted with the 
CRISPR/ Cas9 KO plasmid, a puromycin resistance gene for selection of cells where Cas9-
induced DNA cleavage has occurred. 
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Of the HDR plasmids also a total number of three were used, each containing a HDR 
template corresponding to the cut sites generated by the corresponding CRISPR/Cas9 KO 
plasmids providing a specific DNA repair template for a double strand break (DSB). 
In order to generate ATXN3 KO cell lines, two human patient-derived small molecule neural 
precursor cell lines were nucleofected with the CRISPR/Cas9 system. After nucleofection 
three different KO conditions arised: a knockout of ATXN3 in both alleles (bi-allelic knockout) 
or in only one allele (mono-allelic knockout) of both cell lines, resulting in clones that 
expressed either the non-expanded (ATXN3_non-exp), the expanded (ATXN3_exp) or no 
ATXN3 (ATXN3_KO) as it is depicted in Figure 4.1.  
 
 
 
Figure 4.1: CRISPR/Cas9 strategy for the generation of isogenic iPSC-derived clones with differences in 
the expression of ATXN3.  
Patient-derived small molecule neural precursor cells were nucleofected with the CRISPR/Cas9 plasmid system. 
Depending on which allele CRISPR/Cas9 cuts, the corresponding clones retained no ATXN3 (ATXN3_KO), the 
non-expanded (ATXN3_non-exp) or the expanded (ATXN3_exp) allele.  Consequently, the translated protein 
Ataxin 3 varies in these clones.  
 
 
Nucleofected cells were seeded in clonal density following by selection with puromycin (Fig. 
4.2 A). After 30 days clones were picked, expanded to clonal cell lines and validated. 
Western blot analysis and PCR were performed to screen, which colonies express the non-
expanded/healthy (ATXN3_non-exp), expanded/disease (ATXN3_exp) allele or no ATXN3 
(KO) (Fig. 4.2 B-D). ATXN3_non-exp (healthy = H1, H2) and ATXN3_exp (disease = D1, D2) 
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neural stem cell clones express only the normal or the expanded allele, respectively. Ataxin 3 
of the ATXN3_exp cell lines has a higher molecular weight because of the prolonged poly-
glutamine stretch as the non-expanded form and thus displays a higher band in western 
immuno blots and PCR compared to the non-expanded protein. In the knockout situation 
(KO1, KO2), no ATXN3 is detectable.  
 
 
 
Figure 4.2: Depiction of identities of the generated isogenic neural stem cell lines compared to a non-
patient and a patient control regarding their expression of ATXN3.  
A: Timeline for generation of CRISPR/Cas9 ATXN3 clones based on smNP cells. Nucleofection of smNP cells 
was followed by a recovery phase for three days. Puromycin initially was applied at 0.25 μg/ml at day three and 
increased to 0.5 μg/ml at day seven of the first selection interval. After a recovery phase of 14 days, a second 
selection interval with 0.5 μg/ml (3 days) and 1 μg/ml for one day was performed, followed by a second recovery 
phase for four days. Afterwards, cells were picked, expanded and evaluated by western blot, ICC and stainings 
for marker expression. In order to identify the status of Ataxin3 in clonally expanded cell lines, western blot 
analysis and PCR were performed. B-D: ATXN3_non-exp/healthy (H1, H2) and ATXN3_exp/diseased (D1, D2) 
clones express only the normal or the expanded allele, respectively and display B/C on the western blot and D in 
the PCR as one band for ataxin 3. Disease clones contain the expanded polyQ allele and therefore appear higher 
on the gels because of their larger size. 
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By using a CRISPR/Cas9 system, isogenic cell lines were generated expressing different 
states of Ataxin 3. This enables to investigate how an expansion and/or loss of ATXN3 might 
affect gene expression in human iPSC SCA3 patient-derived neurons. Those clones 
expressing ATXN3, express either the expanded or the non-expanded allele. That makes 
this system especially appealing since the effects and functions of the expanded and non-
expanded form of ATXN3 can clearly be discriminated without interfering with each other. 
Additionally the isogenic cell lines could further be used for disease modeling since the 
ATXN3_exp clones could “mimic” a homozygous state of Machado-Joseph Disease in which 
both alleles code for the expanded form only. 
 
 
4.1.1  Genetic engineering by using CRISPR/Cas9 does not induce chromosomal 
aberrations in neural stem cells 
 
As previously reported the application of CRISPR/Cas9 is associated with off-target cleavage 
events resulting in karyotypic abnormalities (Kim et al., 2015; Schaefer et al., 2017). To 
exclude such events in the generated cell lines, high-resolution SNP-analysis was 
performed. SNP analysis revealed that, in both cell lines, no significant karyotypic alterations 
were generated (Fig. 4.3 A). Since the normal and expanded alleles of ATXN3 are 
hemizygously expressed in ATXN3_non-exp and ATXN3_exp clones, respectively, those 
clones were additionally sequenced to ensure that the remaining allele is without any genetic 
defects in order to code for a functional protein. The sequencing results revealed an intact 
and correct protein sequence for ATXN3 with no off-target alterations (Fig. 4.3 B). One single 
nucleotide exchange was found in the sequencing of all investigated clones as well as in the 
original smNPC lines. Thus, the SNP is not related to the nucleofection of the smNPCs with 
the CRISPR/Cas9 system. It is located at position 561 in the ATXN3 gene and categorized 
as a single nucleotide variation with no clinical significance (rs16999141, see NCBI dsSNP 
data base; Fig. 4.3 B/C). Two clones of each group from both patient-derived cell lines were 
chosen to proceed with experiments (n=12).  
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Figure 4.3: The remaining ATXN3 allele of the hemizygous isogenic cell lines shows no off-target effects 
A: Full genome SNP analysis of the patient-derived cell line without detectable alterations. B: Sequencing 
revealed a complete and correct sequence for ATXN3. One SNP was found which exchanges TC, both coding 
for the amino acid valine. C: Alignment of the protein template of the transcript ATXN3-248 (www.ensembl.org) 
with the protein sequences of the ATXN3 clones revealed no abnormalities in the protein sequence of the clones 
(shown for the clone H1). 
 
 
4.1.2  Isogenic neural stem cells express stem cell-specific markers and differentiate 
into neurons and glia  
 
The isogenic neural stem cells and their differentiated neuronal progeny were further 
characterized for the expression of typical stage-specific proteins and transcription factors 
indicative for their regional identity in the brain axes. Homogenous smNPC lines were 
cultured in the presence of the small molecules CHIR and purmorphamine to stimulate WNT 
signaling and the SHH pathway, respectively, in order to promote the capacity of self-
renewal. To differentiate smNPCs into neurons, the cells were exposed to the growth factors 
FGF2 and EGF for 24h to generate rosette-type neural stem cells (ltNES) and then 
differentiated in the absence of growth factors for five weeks (Fig. 4.4).  
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4.4 Scheme of the differentiation protocol 
Schematic overview showing the protocol for differentiation of iPS cell-derived smNPCs into cultures of 
postmitotic human neurons, which were monitored over five weeks.  
 
 
Immunocytochemical analysis revealed that all investigated smNPCs homogenously express 
the transcription factors SOX2, PAX6, PLZF and DACH1 in the nucleus, the intermediate 
filament nestin and the tight-junction marker ZO-1, which is spatially localized to the apical 
surface (Fig. 4.5 A/C).  
After withdrawal of growth factors, cultures incrementally changed there cellular morphology 
and gave rise to a major number of β-III tubulin as well as MAP2ab-positive postmitotic 
human neurons and a minor number of GFAP- positive astrocytes within five weeks (Fig. 4.5 
B/D). This means that the cells kept their preserved neuronal differentiation potential. Growth 
capacity as well as the differentiation potential in these neurons can be stable for more than 
100 passages. 
Since the cells expressed all typical stem cell markers and markers for the differentiated 
stage, the CRISPR/Cas9 targeting strategy, selection and propagation of clones did not 
significantly alter the characteristics of the modified cells. 
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Figure 4.5: The isogenic smNPC clones expressed marker for the proliferative as well as for the 
differentiated state of cell development equally to the non-clonal healthy and patient controls and can be 
allocated to the hindbrain region 
A/C: Immunofluorescence staining of ATXN3 clones from two cell lines expressing the nuclear marker SOX2, 
PLZF, PAX6 and DACH1, nestin as an intermediate filament and the tight junction marker ZO-1 for the 
proliferative state (scale bar=100µM and 250µM for phase contrast). B/D: Neuronal cultures from two iPS cell-
derived smNPCs clones, differentiated for five weeks, expressing the neural marker β-III tubulin and MAP2ab as 
well as the astrocytic marker GFAP for the differentiated state (scale bar=100µM and 250µM for phase contrast). 
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Since ATXN3 is a major contributor to the induction of the pathology of SCA3, a disease that 
affects mainly the hindbrain (e.g. cerebellum), it was interesting to know which regional 
identity the clones express. All smNPC-derived neural cell lines showed a prominent 
expression of the anterior hindbrain markers HoxA2 and HoxB2, whereas HoxB4 was not 
detectable indicating an anterior hindbrain identity (Fig. 4.6; Koch et al., 2009; Reinhardt et 
al., 2013). 
 
 
Figure 4.6: Isogenic neurons display an anterior hindbrain identity   
Neuronal cultures were differentiated for five weeks and cDNA was generated. PCR revealed an expression of 
the rostrocaudal markers HOXA2 and HOXB2, but no expression of HoxB4 in clones derived from both cell 
lines and their non-isogenic controls. This expresson pattern marks an anterior hindbrain identity.  
 
 
In summary, the ATXN3 clones did not develop karyotypic aberrations, sequencing revealed 
no alterations in the sequence of the remaining allele (KOs were excluded), marker for the 
proliferative state (PAX6, NESTIN, SOX2) as well as for the differentiated state (e.g. betaIII-
tubulin, Map2ab) were expressed and an anterior hindbrain identity can be concluded. 
 
 
4.2 Transcriptional analysis of isogenic human neurons identified metallothioneins to 
be differentially expressed depending on the state of Ataxin 3  
 
Recent data suggest that either conformational changes of the expanded ATXN3 protein 
and/or a loss of free available ATXN3 due to recruitment of ATXN3 into aggregates leads to 
the dysregulation of multiple cellular pathways such as ubiquitination or transcriptional 
regulation (Evert et al., 2006; Haacke et al., 2006). To study the influence of expanded 
and/or loss of ATXN3 on gene expression in patient-specific and CRISPR/Cas9 edited 
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neurons, a gene expression analysis was performed. For the analysis neuronal cultures from 
three clones of each condition in biological duplicates were used. These clones were 
harvested under normal culture conditions and following exposure of the cultures to 100 µM 
L-glutamate to promote a glutamate-induced excitation of patient-derived neurons initiating 
Ca2+-dependent proteolysis of ATXN3 and a subsequent formation of SDS-insoluble 
aggregates (Koch et al., 2011). That allowed not only a genetic-dependent but also a 
treatment-dependent comparison between the clones regarding their response to L-
glutamate as an aggregation-promoting stressor.  
Gene expression analysis revealed 47194 genes of which 14532 remained after pooling 
samples into ATXN3_KO, ATXN3_exp and ATXN3_non-exp groups (n=6/group). The 
remaining 14,532 genes were analyzed to identify transcripts that were differentially 
expressed in ATXN3_KO, ATXN3_exp and ATXN3_non-exp samples with the minimum 
threshold level p<0.001 and and an up- or downregulation of 1.5-fold in gene counts. 
First, a cluster analysis was done which clearly separated L-glutamate treated neurons from 
non-treated neurons. In addition, within both groups, those cultures where ATXN3 remained 
(ATXN3_non-exp and ATXN3_exp) cluster together and separate from the same branch 
whereas the ATXN3_KO clones are branching before (Fig. 4.7 A).  
The more detailed gene expression analysis revealed a number of differentially expressed 
genes between the ATXN3 clones (Fig. 4.7 A-J) and that the strongest differences in the 
number of differentially expressed genes in the untreated condition are between ATXN3_KO 
and ATXN3_non-exp (Fig. 4.7 B/E), followed by ATXN3_KO versus ATXN3_exp (Fig. 4.7 
C/F). In comparison, the differences between ATXN3_non-exp and ATXN3_exp are minor  
(Fig. 4.7 D/G). Following L-glutamate treatment, the number of differentially expressed genes 
between ATXN3_KO and ATXN3_non-exp is similar to that between ATXN3_KO and 
ATXN3_exp (Fig. 4.7 H/I). Still, the lowest number is observed when comparing gene 
expression between ATXN3_non-exp and ATXN3_exp neuronal cultures (Fig. 4.7 J).  
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Figure 4.7: Differentially expressed genes in isogenic neuronal cultures  
Gene expression studies were performed on five-week-old neuronal cultures from three clones of each condition 
(ATXN3 KO, expanded, non-expanded) in biological duplicates under normal culture conditions and following 
exposure of the cultures to 100 µM glutamate (2TX). All clones of each condition were pooled into a 
corresponding group A: Cluster analysis showing an allocation of the cell lines into a L-glutamate- and a non-
treated cluster. In both clusters, ATXN3_exp and ATXN3_non-exp neuronal cultures are genetically closer related 
to each other than to ATXN3_KO. B-G: Several genes are differentially regulated under non-treated experimental 
conditions and (H-J) L-glutamate treatment between ATXN3_KO and the two other clone groups, with the most 
apparent differences between ATXN3_KO and ATXN3_non-exp.  (n=6 for each group)   
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Differently expressed genes did not show significant enrichment for a specific pathway using 
gene ontology analysis. However, four of the most significant downregulated genes in 
ATXN_KO cells compared to ATXN3_non-exp cells belonged to the same functional cluster 
of metallothioneins (MT1A, MT1E, MT1G and MT2A; Fig. 4.8 A-I). 
All four MT genes were significantly downregulated in ATXN3_KO compared to ATXN3_non-
exp and ATXN3_exp neurons. Additionally, these genes seem to display a higher expression 
in ATXN3_exp than ATXN3_non-exp neurons but this trend was not significant (Fig. 4.8 A-
D).     
After L-glutamate treatment, the expression levels of all MTs increased in all cell lines, but 
again, remained comparatively downregulated in ATXN3_KO neuronal cultures (Fig. 4.8 E-
H). Also under treated experimental conditions a non-significant trend of higher expression 
levels in ATXN3_exp compared to ATXN3_non-exp cells was observable for each gene.  
The up-regulation of metallothioneins after glutamate-treatment is also shown in a heatmap 
displaying MT expression (Fig. 4.8 I). MT1F and MT1X were excluded from further studies 
since their expression profile does not significantly differ between the clonal groups. 
Metallothioneins play a crucial role in the cellular response towards metal stress and 
maintenance of metal homeostasis (Hidalgo et al., 2001; Margoshes and Vallee, 1957; 
Thirumoorthy et al., 2011). In addition to the regulation of metal levels, metallothioneins are 
also involved in the cellular stress response by protecting against oxidative stress (Takahashi 
et al., 2012; Ruttkay-Nedecky et al., 2013). 
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Figure 4.8: Gene expression analysis revealed a downregulation of a metallothionein cluster in 
ATXN3_KO neurons compared to neurons expressing the expanded or non-expanded allele 
A-D: Gene expression level depicted as average signal intensity for the metallothioneins MT1A, MT1E, MT1G 
and MT2A (n=6 for each group). E-H:  Expression levels after application of 100 µM L-glutamate. (n=6 for each 
group). I: Heat map of the MT gene cluster expression for each clone (duplicates pooled). P < 0.05 and delta > 
1.5. Each column represents a clone and each row represents a single gene. The left half of the heat map shows 
gene expression I the untreated condition, the right half shows expression after applying 100 µM L-glutamate. 
Expression levels are colored green for low intensities and red for high intensities (n=36 in total). *p<0.05; 
**p<0.01 
 
 
 
4.2.1  Quantitative real-time PCR verifies the metallothionein gene cluster to be 
differentially expressed depending on the state of Ataxin3 in isogenic human neurons  
 
In order to verify the results of the gene expression analysis, quantitative real-time PCR was 
performed for MT1A, MT1E, MT2A and MT1G. This analysis confirmed that the cluster of 
metallothioneins is downregulated in ATXN3_KO neurons compared to ATXN3_non-exp and 
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ATXN3_exp cells and that the highest expression of MTs is detected in ATXN3_exp neurons 
(Fig. 4.9 A-D). Furthermore, the analysis confirmed that the application of L-glutamate 
increases the expression of all four metallothioneins in comparison to the untreated 
condition. Again, a similar pattern was observed with the lowest expression in ATXN3_KO 
and the highest expression in ATXN3_exp neurons (Fig. 4.9 E).  
Since MTs are important for cellular metal homeostasis, the isogenic clones were further 
treated with the heavy metal CdCl2 [25µM]. The treatment with 25µM CdCl2 had an even 
stronger impact on the expression levels of MTs (Fig. 4.9 F). Furthermore, it changed the 
expression levels in ATXN3_non-exp and ATXN3_exp cultures to the effect that 
ATXN3_non-exp neurons now displayed the highest levels of metallothionein expression and 
the expression levels of ATXN3_exp neurons were comparable to ATXN3_KO cells.  
 
 
 
Figure 4.9 Metallothionein expressions in the isogenic cell lines derived from patient 2 
A-D: qPCR was done for MT1A, MT1E, MT1G and MT2A. For all genes, the data show that they are significantly 
downregulated in ATXN3_KO compared to the two other groups and that the expression is highest in ATXN3_exp 
neurons. E: Cells which were treated with 100 µM glutamate (2TX) showed in general a higher expression of the 
gene compared to non-treated cells  (here with MT1G) but still with the highest expression in clones with the 
expanded allele. F: After treatment with 25 µM CdCl2, the expression level further increased and the pattern 
between ATXN3_exp and ATXN3_non-exp neurons was exchanged, with the highest expression now in those 
clones with the non-expanded allele (n=6 for each group). Bar graphs show mean ± SD of each group. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. 
 
 
The qPCR analysis was further repeated on isogenic neurons derived from the second 
patient. Interestingly, ATXN3_exp neurons derived from patient two showed an expression 
profile more similar to ATXN3_KO than to ATXN3_non-exp clones already in the untreated 
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condition (Fig. 4.10 A-D). In line with the results from the previous patient cell line the 
expression level of MTs increased with the treatment of L-glutamate and even more with 
CdCl2 (Fig. 4.10 E/F). Under all conditions, the expression of MTs was lowest in ATXN3_KO 
and highest in ATXN3_non-exp neurons, with ATXN3_exp in between.    
Together, these data demonstrate that, for both cell lines, the expression levels of MTs are 
lowest in ATXN3_KO neurons compared to the ATXN3-containing neurons and that the 
expression pattern of ATXN3_exp and ATXN3_non-exp neuronal cultures varies between 
the two patient-derived isogenic clones under non-treated and L-glutamate-treated 
conditions. This variation disappears after the application of a strong stressor such as the 
heavy metal CdCl2 with the result that the MT-expression is highest in ATXN3_non-exp 
neurons in both cell lines.   
 
 
 
Figure 4.10 Metallothionein expression in the isogenic cell lines derived from patient 2 
A-D: qPCR was performed for MT1A, MT1E, MT1G and MT2A on a second patient-derived cell line. The genes 
are significantly downregulated in ATXN3_KO compared to ATXN_exp and ATXN3_non-exp neurons, with the 
highest expression in clones with the non-expanded allele. E: Cells, which were treated with 100µM glutamate 
(2TX), showed in general a higher expression of the MTs compared to non-treated cells (here with MT1G) but still 
with the highest expression in the non-expanded clone condition. F: The highest expression of MTs was achieved 
after treatment with 25 µM CdCl2, with the same expression pattern as in untreated and L-glutamate treated cells 
(n=6 for each group). Bar graphs show mean ± SD of each group. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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4.3 Loss of ATXN3 increases neuronal susceptibility to stress  
 
Since metallothioneins are important regulators of cell homeostasis and participate in an 
array of protective stress responses such as metal and oxidative stress, it was inevitable to 
investigate if the loss of ATXN3, either due to a KO or due to the formation of aggregates 
(ATXN3_exp), results in an influence on the regulation of cell homeostasis by increasing the 
susceptibility to oxidative, metal-, or excitotoxicity-related stress conditions. To test this, five-
week-old neurons of two patient-derived neural cell lines were exposed to rotenone, CdCl2, 
ZnCl2 and L-glutamate for 48 h in different concentrations. Afterwards, a cell viability assay 
was performed which demonstrated that ATXN3_exp and ATXN3_KO neurons were indeed 
more susceptible to several types of cellular stress than ATXN3_non-exp, resulting in a 
higher number of cell survival in ATXN3_non-exp neurons (Fig. 4.11 A-D).  
After rotenone treatment the cell survival rate of ATXN3_non-exp neurons was significantly 
higher than in ATXN3_KO and ATXN3_exp at 5 µM (38,86% ± 17,13% vs 16,36% ± 5,56% 
and 24,34% ± 8,07%), 25 µM (26,7% ± 13,21% vs 13,43% ± 4,21% and 19,19% ± 6,14%) 
and 50 µM (19,25% ± 7,85% vs 10,75% ± 2,52% and 13,33% ± 3,14%).  
Similar results were achieved with the administration of the metals CdCl2 10 µM (110,54% ± 
3,99% vs 90,20% ± 12,44% and 104,32% ± 7,16%), 25 µM (80,29% ± 12,09% vs 42,51% ± 
11,27% and 54,62% ± 10,47%), 50 µM (35,37% ± 13,70% vs 13,6% ± 5,78% and 20,86% ± 
7,46%) and ZnCl2 100 µM (99,81% ± 12,77% vs 77,32% ± 14,64% and 89,36% ± 7,06%); 
150 µM (72,11% ± 14,39% vs 41,04% ± 11,83% and 61,17% ± 12,57%) 200 µM (42,34% ± 
10,92% vs 12,56% ± 5,52% and 24,31% ± 12,18%). 
Finally, also after treatment with the exitotoxicity stressor L-glutamate 2 mM (92,6% ± 7,12% 
vs 89,05% ± 6,26% and 93,06% ± 20,12%), 5 mM (83,82% ± 4,82% vs 59,48% ± 15,92% 
and 76,46% ± 11,28%) and 7.5 mM (50,47% ± 12,14% vs 23,06% ± 12,75% and 25,96% ± 
16,44%) ATXN3_non-exp neurons displayed a higher cell survival rate than the two other 
groups. No significant differences were found for the treatment with rotenone 50µM and 
ZnCl2 200 µM.  
Overall, the cell survival assay demonstrates that ATXN3 is crucial for the cellular response 
towards oxidative, metal and excitotoxic stress. 
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Figure 4.11: Neurons expressing either the expanded or no ATXN3 are more sensitive to oxidative, metal 
and excitotory stress than neurons, which express the non-expanded allele  
Neuronal cultures were seeded in 96-well plates and cultured for four weeks, followed by a treatment of neural 
cultures with different stressors (A-D) Afterwards, a cell survival assay was performed. Graphs show the relative 
cell survival rate [%] of ATXN3_non-exp, ATXN3_exp and ATXN3_KO neurons after exposure to A: Rotenone 5, 
25 and 50 µM, B: CdCl2 10, 25 and 50 µM, C: ZnCl2 100,150 and 200 µM and D: Glutamate 2, 5 and 7.5 mM for 
48 hours, respetively. For each group two clones with technical triplicates were used (n=6 / group). Bar graphs 
show mean ± SD of each group. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
 
 
The same experiment was performed on ATXN3_KO, ATXN3_exp and ATXN3_non-exp 
neurons of a second iPSC-derived patient cell line, displaying comparable results (Fig. 4.12 
A-D).  
ATXN3_non-exp neurons showed a significantly higher survival rate than ATXN3_KO and 
ATXN3_exp neurons after treatment with rotenone 5 µM (33,3% ± 7,8% vs 21,16% ± 8,48% 
and 24,75% ± 6,39%), 25 µM (31,31% ± 5,91% vs 17,57% ± 8,05% and 17,49% ± 5,1%) and 
50 µM (22,42% ± 6.04% vs 11.51% ± 5,91% and 14,64% ± 5,23%). 
The number of surviving ATXN3_non-exp neurons was also higher compared to ATXN3_KO 
and ATXN3_exp cells after exposure to the metals CdCl2 10 µM (100,7% ± 11,56% vs 
68,56% ± 9,2% and 66,59% ± 13,84%), 25 µM (52,24% ± 12,74% vs 36,97% ± 4,9% and 
41,55% ± 6,67%) and 50 µM (31,63% ± 11,67% vs 20,93% ± 9,2% and 16,29% ± 4,91%), 
and ZnCl2 100 µM (88,49% ± 10,91% vs 66,26 ± 5,35% and 75,77% ± 10,13%), 150 µM 
(71,13% ± 13,97% vs 39,9% ± 14,07% and 45,15% ± 10,16%) and 200 µM (30,65% ± 
10,62% vs 17,46% ± 11,53% and 22,95% ± 4,92%) as well as the exitotoxicity stressor L-
glutamate at 2 mM (98,67% ± 0,72% vs 61,57% ± 1,02% and 89,22% ± 6,14%)  5 mM 
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(64,91% ± 7,21% vs 49,96% ± 0,42% and 56,79% ± 3,74%)  and 7.5 mM (42,71% ± 4,52% 
vs 27,39% ± 1,67% and 31,04% ± 2,6%).  
No significant differences were found for the treatment with 2 mM glutamate. 
 
 
 
Figure 4.12: Neurons derived from a second patient line expressing either the expanded or no ATXN3 are 
as compared to the first patient line as well more sensitive to different stressors than neurons which 
express the non-expanded allele  
Graphs show the relative cell survival rate [%] of ATXN3_non-exp, ATXN3_exp and ATXN3_KO neurons, derived 
from a second patient line, after exposure to A:  Rotenone 5, 25 and 50 µM, B: CdCl2 10, 25 and 50 µM, C: ZnCl2 
100,150 and 200 µM and D: Glutamate 2, 5 and 7.5 mM for 48 hours, respetively. For each group two clones with 
technical triplicates were used (n=6 / group). Bar graphs show mean ± SD of each group. *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001 
 
 
Based on the result that in comparison to ATXN3_non-exp neurons, ATXN3_KO and 
ATXN3_exp neurons showed a disturbance of the neuronal homeostasis and an increased 
susceptibility to stress, it was evaluated if such a phenotype can also be found when 
comparing neurons from a patient with that of healthy controls in a non-isogenic scenario. 
For that purpose, two iPSC-derived patient and two control neuronal cell lines were exposed 
to the same stressors.  
The two healthy control cell lines showed a higher number of surviving cells compared to the 
two patient control cell lines after treatment with rotenone 5 µM (60,02 ± 0,64% vs 30,48% 
±2,09%), 25 µM (48,74% ± 5,61% vs 18,01% ± 3,07%) and 50 µM (39,04% ± 6,28% vs 
15,44% ± 0,96%), CdCl2 10 µM (92,31% ± 28,12% vs 93,28% ± 3,51%), 25 µM (87,93% ± 
-Results- 
_____________________________________________________________________________________________________ 
 61 
14,11% vs 48,0% ± 4,08%) and 50 µM (60,66% ± 3,51% vs 22,45% ± 5,66%), ZnCl2 100 µM 
(93,0 ± 2,05% vs 88,73%± 4,53%), 150 µM (72,15% ± 5,0% vs 62,37% ± 2,37%) and 200 
µM (41,96% ± 8,81% vs 22,99% ± 3,58%), as well as the excitotoxicity stressor L-glutamate 
at 2 mM (87,03% ± 0,82% vs 70,47% ± 2,55%), 5 mM (73,82% ± 1,61% vs 53,35% ± 0,59%)  
and 7.5 mM (41,9% ± 0,01% vs 32,94% ± 0,45%) (Fig. 4.13 A-D).  
 
 
 
Figure 4.13: Patient iPSC-derived neurons react more sensitive to oxidative, metal and excitotory stress 
than the healthy control neurons.  
Graphs show the relative cell survival rate [%] of two healthy and two patient control neurons after exposure to A:  
Rotenone 5, 25 and 50 µM, B: CdCl 10, 25 and 50 µM, C: ZnCl 100,150 and 200 µM and D: Glutamate 2, 5 and 
7.5 mM for 48 hours, respetively. For each group two clones with technical triplicates were used (n=6 / group). 
Bar graphs show mean ± SD of each group. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
 
 
Since the ATXN3_exp neurons as well as the patient derived non-clonal neurons displayed a 
lower cell survival rate than their control cell lines with a non-expanded allele of ATXN3, it 
was interesting to address the question of possible consequences resulting from induced 
aggregation in healthy control neurons. To answer this question, a lentiviral construct was 
generated overexpressing the polyQ fragment of ATXN3 since this fragment is believed to be 
a toxic species and responsible for the aggregation of ATXN3. It was assumed that neurons 
transfected with a construct expressing only the c-terminal polyQ fragment of ATXN3, might 
show a lower cell survival rate than the control neurons. Therefore, healthy control smNPCs 
were transduced with a lentiviral Tet-On 3G inducible expression system and the lentiviral 
vector pLVXTP-ATXN3_C71 expressing the truncated form of ATXN3 (Fig. 4.14 A). Before 
the accession of the cell viability, progenitors as well as their arising five-week-old neural 
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cultures were stained for ATXN3-containing aggregates after treatment with doxycycline. 
Non-treated cells were taken as a negative control for the formation of aggregates. Both, 
progenitors and neurons, displayed aggregates, which were only visible after doxycycline 
treatment in immunocytochemical stainings and a slot blot assay (Fig. 4.14 B/C). In both cell 
populations, smNPCs and neurons, the number of cells containing aggregates was around 
40-45 % (Fig. 4.14 D/E).  
 
 
 
Figure 4.14: smNPCs and neurons transduced with a viral vector of an ATXN3 construct, expressing a 
truncated, only c-terminus containing form, efficiently formed intranuclear aggregates.  
A: Schematic representation of the lentiviral constructs for doxycycline-inducible overexpression of ATXN3_C71: 
The pLVX-EtO vector carries the tetOn protein rtTAAdv and an IRES-linked neomycin resistance gene (neoR), 
which are both controlled by an EF1α promoter (upper panel). The lower panel shows the full-length and the 
truncated form of the ATXN3 gene. The truncated form was cloned into a pLVXTP vector and the resulting 
pLVXTP-ATXn3_C71 vector contains the coding sequence for ATXN3_C71 under the control of the inducible 
TREtight promoter as well as a puromycin resistance gene (puroR) driven by aPGK promoter B: 
Immunocytochemistry of smNPCs and five-week-old differentiated neurons transfected with the truncated form of 
ATXN3 revealed the formation of ATXN3 positive inclusions under doxycycline induction (scale bar=100µm) C: 
Slot blot analysis using the polyQ-specific 1C2 antibody to detect aggregates after induction with doxycycline. 
Sample without doxycycline was used as a negative control. D:  Bar graph shows the relative number of smNPCs 
containing intranuclear aggregates. E: Bar graph shows the relative number of -II-tubulin positive neurons 
expression aggregates. Bar graphs show mean ± SD of each group. **p<0.01; ****p<0.0001 
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Following a five-week differentiation period, the cell viability of neuronal cultures was 
evaluated in the presence and absence of cellular stress. The cell viability assay revealed 
that those cultures, forming lentiviral-induced aggregates after doxycyline treatment, showed 
decreased cell survival numbers compared to neurons without doxycycline treatment after 
application of different stressors such as rotenone 5 µM (44,33% ± 9,92% vs 36,45% ± 
7,61%), 25 µM (44,21% ± 7,64% vs 30,08% ± 2,24%) and 50 µM (32,88% ± 7,00% vs 
22,96% ± 1,78%).  
Similar results were achieved with the administration of the metals CdCl2 25 µM (78,86% ± 
9,77% vs 76,96% ± 8,17%), 50 µM (51,29% ± 4,04% vs 31,90% ± 4,72%) and 100 µM 
(25,93% ± 7,30% vs 23,88% ± 8,21%) as well as ZnCl2 100 µM (85,15% ± 7,30% vs 90,00% 
± 11,66%), 150 µM (79,88% ± 9,01% vs 50,63% ± 18,44%) and 200 µM (30,00% ± 9,50% vs 
27,33% ± 12,01% and the exitotoxicity stressor L-glutamate at 2 mM (87,91% ± 5,08% vs 
67,09% ± 10,04%), 5 mM (68,54% ± 12,17% vs 49,44% ± 1,12%) and 7.5 mM (26,16% ± 
7,35% vs 16,96% ± 7,42%) (Fig. 4.15 A-D).  
 
      
Figure 4.15: Doxycycline-dependent cells expressing the truncated form of ATXN3 display the same 
phenotype that was observed in ATXN 3 clones and their non-clonal controls  
A-D: Graphs show the relative cell survival rate [%] of neurons without (-DOX) and with (+DOX) doxycycline 
treatment after exposure to A:  Rotenone 5, 25 and 50 µM, B: CdCl2 10, 25 and 50 µM, C: ZnCl2 100,150 and 
200 µM and D: Glutamate 2, 5 and 7.5 mM for 48 hours, respectively. For each group technical triplicates were 
used (n=3 / group). Bar graphs show mean ± SD of each group. *p<0.05; **p<0.01; ***p<0.001. 
 
 
Additionally, the cell numbers of untreated controls were compared between doxycycline-
dependent and non-dependent cells. No significant differences in the cell survival rates were 
found (Fig. 4.16). This indicates that the aggregates are not toxic to the neurons and that the 
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differences in the number of surviving cells are related to the absence or presence of 
ATXN3, which supports the hypothesis of ATXN3 being involved in the cellular response to 
stress.   
 
 
 
 
4.4 Depletion of Ataxin3 in human neurons results in an increased susceptibility 
towards total ROS and superoxide formation  
 
Loss of or defective ATXN3 in neurons might critically affect vital cellular functions and thus 
cell survival as it was shown in the section 4.5. Considering that metallothioneins are 
crucially involved in the generation and clearance of reactive oxygen species (ROS; Ruttkay-
Nedecky et al., 2013; Sato et al., 1993), it was investigated if the ATXN3_ KO neurons might 
have a lower capacity to cope with increasing amounts of total ROS and superoxide during 
oxidative stress. For this, level of total ROS and superoxides were measured in five weeks 
differentiated neurons after exposure to oxidative stress. As antioxidants are present in 
standard media conditions (B27 supplement contains high levels of multiple antioxidants 
such as sodium pyruvate, catalase and superoxide dismutase) these experiments were 
performed under basal culture conditions not containing any antioxidants (medium without 
B27 supplement).  
ROS and superoxide production were induced by exposing neural cultures to pyocyanin in 
different concentrations [0 µM, 150 µM, 300 μM and 500 μM] for 1h. Levels were measured 
by a fluorescent assay (Fig. 4.17 A/B, right graphs).  
The pyocyanine-induced increase of ROS/superoxide at all concentrations was significantly 
highest in ATXN3_KO neurons (total ROS: 160,28% ± 2,20%, 199,02% ± 2,62% and 
251,47% ± 15,35%; superoxide: 165,67% ± 5,86%, 191,20% ± 14,09% and 201,98% ± 
23,61%), followed by ATXN3_exp (total ROS: 158,38% ± 11,61%, 170,31% ± 6,59% and 
232,09% ± 21,22%; superoxide: 138,60% ± 3,10%, 136,39% ± 14,4% and 165,61% ± 
31,27%) and lowest in ATXN3_non-exp neurons (total ROS: 111,11% ± 5,05%, 126,5% ± 
13,09% and 251,47% ± 28,34%; superoxide: 106,99% ± 1,51%, 116,95% ± 2,88% and 
Figure 4.16: Aggregates inherently are not 
toxic to doxycycline-dependent neurons 
expressing the truncated form of ATXN3  
Graphs show the relative cell survival rate [%] of 
neurons without (-DOX) and with (+DOX) 
doxycycline treatment under normal culture 
conditions. For each group technical triplicates 
were used (n=3 / group). Bar graphs show mean 
± SD of each group.  
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125,49% ± 6,06%) compared to the control (Fig. 4.17). These data indicate that ATXN3 plays 
an important role in the processing of oxidative stress and the accompanied regulation of 
total ROS and superoxide levels by mediating the expression of metallothioneins. 
 
 
 
 
4.5 The metal regulatory transcription factor 1 expression does not differ between 
isogenic clones 
 
Since the clones displayed a strong phenotype regarding the ATXN3-dependent cellular 
stress response, it was important to decipher a possible underlying mechanism. It was 
shown before that the expression of metallothioneins is induced through the transcription 
factor MTF-1 (metal regulatory transcription factor 1). This transcription factor directly 
responds to metal and oxidative stress by binding to the metal-responsive element of the MT 
gene, which initiates its transcription. This autoregulatory loop is mandatory for the regulation 
of a normal intracellular level of metals and to reduce oxidative stress in cells (Fujie et al., 
2016; Heuchel et al., 1994; Pamiter et al., 1994; Ruttkay-Nedecky et al., 2013). Therefore, 
MTF-1 was chosen as a candidate to decipher the mechanism of an ATXN3-dependent 
regulation of MTs. The cDNA expression levels of MTF-1 between the three groups and 
between single clones were compared. qRT-PCR and PCR revealed no significant 
Figure 4.17: Ataxin3_KO neurons are 
more sensitive to oxidative stress 
than ATXN3_exp and ATXN3_non-exp 
neurons  
A/B: Induction of total ROS (green) and 
superoxide (red) after pyocyanin 
treatment (0 µM,150 µM, 300 μM und 
500µM, 1 h) is highest in ATXN3_KO 
clones and lowest in ATXN3_non-exp 
clones. Bar graphs show mean ± SD of 
each group.  
*p <0.05; **p<0.01; ***p <0.001; **** 
p<0.0001. 
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differences in the expression profile between groups and single clones (Fig. 4.18 A-C). 
Conclusively, the stress response and concomitant the regulation of the metallothionein 
cluster might occur posttranscriptionally on protein level. 
       
       
 
To exclude the possibility that other metallothionein interaction partners except MTF-1 might 
contribute to the clonal phenotype, the expression of genes that are known to interact with 
metallothioneins were analyzed. 
By using the transcription tool of enrichr (http://amp.pharm.mssm.edu/Enrichr/enrich), a 
cluster was generated that constitutes different factors whose pathways are connected to 
metallothioneins (Fig. 4.19 A). For all of these genes, except for MTF-1, the expression data 
of the neural cultures revealed an expression level beneath the significance border, which 
means, according to the array of the gene expression study, those genes are not expressed 
in the neural cultures (Fig. 4.19 B). One exception is the aryl hydrocarbon receptor (AHR), 
which is highly expressed in the neural cultures (Fig. 4.19 C). Sato et al. (2013) described a 
mechanism whereby AHR modulates expression of human MT2A via the glucocorticoid 
response element and protein-protein interactions with GR. Since the interaction of AHR in 
this study is restricted to MT2A and none of the other members of the metallothionein family, 
this gene was excluded as a candidate gene. 
Therefore, MTF-1 remained as a candidate gene for further experiments regarding the 
Figure 4.18: qPCR results for the expression 
of MTF1 
qRT-PCR showed no differences in the 
expression of MTF1 between A the clonal 
groups (two clones pooled, n=6) and B between 
single clones (n=3 per clone). C: PCR analysis 
did not show differences in the expression level 
of MTF1 between clones.  
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understanding of a mechanism how ATXN3 might be involved in the regulation of 
metallothionein expression. 
 
 
 
  
 
 
 
 
4.6   Metal stress-induced nuclear translocation of MTF-1 
 
The activation of MT expression is only possible when MTF-1 migrates into to nucleus in 
order to bind to the metal-regulated enhancer element (MRE) of MT promoters, before and 
after cell stress induction. To test for this, neural cultures transduced with the doxycycline 
dependent lentiviral VSV tagged MTF-1 were exposed to 25 µM CdCl2 and harvested after 
24 h. The obtained cell lysates were fractionated into a cytoplasmic and nuclear fraction by 
centrifugation and a western immunoblot analysis was performed (Fig. 4.20). Indeed, MTF-
1_VSV was also found in the nucleus before stress application, but the highest amount of 
MTF-1_VSV was present in the nuclear fraction in those cells that were cultured in 
doxycycline conditions and exposed to the CdCl2 stress. This suggests that MTF-1 
translocates into the nucleus under stress conditions. In contrast, ATXN3 could not be 
detected in the nucleus at all.  
 
Figure 4.19: Expression analysis of 
metallothionein interaction partners    
A: Enrichr-generates network of genes, which 
are associated with the expression of 
metallothioneins and B their expression levels 
in the gene expression analysis. The red line 
indicates the significance border (p<0.5) of a 
gene being expressed. Of these genes, only 
MTF-1 is significantly expressed.  
 C: Gene expression of the aryl hydrocarbon receptor (AHR). There are no significant differences in its 
expression between the three groups of clones. 
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Figure 4.20: Nuclear fractioning of cell lysates obtained from neural cultures displays a translocation of 
MTF-1 into the nucleus after applying 25 µM CdCl2. 
Upper lane shows the signal for the VSV-tagged MTF-1 whose expression is doxycycline-dependent. After 
treatment with 25 µM CdCl2, MTF-1 translocates, in all clones, into the nucleus. Whereas ATXN3 (#986, second 
lane) cannot be found in the nucleus in treated or untreated condition. The histone antibody H3 is the marker for 
the nuclear fraction. Actin is the loading control. 
 
 
4.7   ATXN3 might be involved in the regulation of the metallothioneins e.g. by 
transcriptional control via its deubiquitinating function 
 
ATXN3 is classified as a deubiquitinating enzyme (Amerik et al., 2004). As that, ATXN3 
might also regulate the activity of MTF-1 via its deubiquitinating function. Following this 
hypothesis, a difference in the stability of MTF-1 would be expected between those clones 
expressing ATXN3 and ATXN3_KO since MTF-1 should be protected from proteasomal 
degradation due to ATXN3-mediated deubiquitination. To test this hypothesis, a 
cycloheximide chase experiment was performed. Cycloheximide blocks the synthesis of new 
proteins, which allows tracking the degradation of MTF-1 in neural cultures over a defined 
period of time. As commercial available antibodies did not show any specific band of the 
expected size in protein western blots, a VSV-tagged MTF-1 was cloned into a lentiviral 
vector (similar to Fig. 4.14, upper panel). By using an antibody against the VSV tag, western 
immunoblotting revealed that in ATXN3_KO and ATXN3_exp cultures MTF-1_VSV was 
degraded significantly faster after 24h as in clones with the non-expanded allele (ATXN3_KO 
vs. ATXN3_non-exp: 49,8% ± 11,26% vs. 84,99% ± 13.82%, ****p<0.0001; ATXN3_exp vs. 
ATXN3_non-exp: 67,8 ± 15% vs. 84,99% ± 13.82%, *p<0.05; ATXN3_KO vs. ATXN3_exp: 
49,8% ± 11,26% vs. 67,8 ± 15%, **p<0.01). Also after 48h of chase the amount of MTF-
1_VSV was significantly lower in ATXN3_KO but not ATXN3_exp neurons compared to 
ATXN3_non-exp neurons (38,75% ± 13,39% vs. 55,2% ± 15,76%, *p<0.05). After 72h no 
significant differences in the remaining MTF-1_VSV between groups could be observed (Fig. 
4.21).  
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If ATXN3 interacts with MTF-1 in order to regulate the expression of MTs e.g. due to 
deubiquitination of MTF-1, an overexpression of MTF-1 in ATXN3_KO should lead to an 
improvement of cell survival rates. Therefore, neuronal cultures were transduced with a 
doxycycline-dependent lentivirus overexpressing VSV-tagged MTF-1. After five weeks of 
differentiation, the cell viability was evaluated after exposure to CdCl2 at different 
concentrations to access cell survival rates. The cell viability assay revealed that MTF-
1_VSV overexpression significantly increased cell survival rates in ATXN3_non-exp and 
ATXN3_KO but not in ATXN3_exp cells after applying CdCl2 at the lowest concentration [10 
µM]. At 25 µM CdCl2 only a non-significant trend towards an increased cell survival under 
doxycycline conditions could be observed in all groups. However, 50 µM CdCl2 does not 
affect the cell survival rates between MTF-1_VSV expressing and non-expressing neurons 
(Fig. 4.22). 
 
Figure 4.21:  Cycloheximide chase reveals 
a higher stability of MTF1_VSV in 
ATXN3_non-exp than ATXN3_KO neurons 
A: Western immunoblots of a 72h 
cycloheximide chase [100 µg/ml]. Two clones 
of each group of ATXN3_non-exp, 
ATXN3_exp and ATXN3_KO neurons were 
used. B: Graph shows the remaining signal 
of MTF1_VSV in [%] over time (n=3 for each 
clone).  
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Figure 4.22:  MTF-1_VSV overexpression 
significantly increases cell survival rates 
in ATXN3_non-exp and ATXN3_KO but 
not in ATXN3_exp neurons after 
application of CdCl2 at low 
concentrations  
Neuronal cultures were transduced with a 
lentivirus overexpressing MTF-1_VSV, 
seeded in 96-well plates and cultured for 
five weeks. Cells were cultivated in medium 
containing doxycycline, whereas controls 
maintained in doxycycline-free medium.  
 Graphs show the relative cell survival rates [%] of ATXN3_non-exp, ATXN3_exp and ATXN3_KO neurons after 
exposure to CdCl2 10, 25 and 50 µM for 24 hours. For each group two clones with technical triplicates were 
used (n=6 / group). Bar graphs show mean ± SD of each group. *p<0.05; **p<0.01. 
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5 Discussion 
 
Transcription is the first step for gene expression and is influenced by epigenetic 
modifications (DNA-methylation or histone-modification) or transcriptional regulators 
including transcription factors and co-regulators. Depending on the regulation mechanism, 
transcriptional regulators are able to interfere in an activating or inhibiting manner and thus 
allowing the cell to react to changes in environmental conditions in order to maintain 
homeostasis.  
Results from previous studies indicate that Ataxin 3 is involved in the progress of gene 
regulation, for instance by regulating the stability of transcriptional regulators via its 
deubiquitinating function. Transcription factors of transcriptional co-regulators might also be 
recruited to nuclear inclusions resulting in an unavailability of these proteins to fulfill their 
physiological tasks (Chai et al., 2001; McCampbell et al., 2000). Another hypothesis 
suggests that the non-expanded, but not the expanded form of ATXN3 acts as a 
transcriptional co-repressor due to formation of repressor complexes and histone 
deacetylation (Evert et al., 2006). 
Metallothioneins were discovered in 1957 by Margoshes and Vallee and identified as low-
molecular weight and cysteine rich proteins. The metallothionein family is evolutionarily 
conserved and proteins are localized in cytoplasm and cell organelles, predominantly in 
mitochondria (Banerjee et al., 1982). MTs are substantial to homeostasis of the essential 
micronutrients zinc and copper, and further for the detoxification of the toxic metal cadmium. 
Additionally, they play a role in radical scavenging, maintenance of cellular redox state and 
oxidative stress response against reactive oxygen species  (Babula et al. 2012; Bremner and 
Beattie 1990; Isani and Carpene 2014; Vasak and Meloni 2011). The expression of 
metallothioneins can be induced by a variety of physiological and environmental stresses 
such as heavy metals, oxidizing agents, oxidative stress and hypoxia (Babula et al., 2012; 
Ruttkay-Nedecky et al., 2013; Saydam et al., 2003). 
The present thesis showed that ATXN3 might be involved in the transcriptional regulation of 
the gene expression of metallothioneins, which is mandatory for the cell to respond to 
different stress events. Gene expression analysis and qRT-PCR results revealed reduced 
expression levels of MTs in ATXN3_KO and ATXN3_exp neurons compared to ATXN3_non-
exp neurons. Consistent with this, the cell survival rate after exposure to metal, oxidative or 
excitotoxic stress was higher in ATXN3 non-exp neurons compared to the two other groups. 
Furthermore, ROS and superoxide levels were elevated in ATXN3_KO and ATXN_exp 
neurons compared to ATXN3_non-exp neurons, indicating that ATXN3 is involved to cope 
with increasing amounts of total ROS and superoxide during cell stress. 
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5.1 CRISPR/Cas9 for the generation of isogenic patient-derived stem cell-derived 
neural stem cells  
 
The recent emergence of CRISPR/Cas9 technology provides a promising tool to overcome 
obstacles such as difficulties of protein design, synthesis and validation that occurred when 
using zinc finger nucleases (ZFNs) and TAL effector nucleases (TALENs). It is a 
straightforward two-component system, operating via Watson-Crick base pairing by a guide 
RNA to identify target DNA sequences and allows precise alterations of any target site. 
Since the isogenic populations produced with CRISPR/Cas9 technology ideally only differ in 
one specific locus, they offer possibilities to overcome cell line specific differences and 
genetic variations of non-isogenic controls, which might mask disease-relevant changes. 
Often, control cells for experiments with patient-specific iPS-cell derived populations are 
obtained from healthy individuals, such as siblings, without knowing if those individuals will 
suffer from a late-onset neurodegenerative disease later in their lives. Furthermore, also 
monogenetic diseases such as Machado-Joseph disease display variation in its time of onset 
or severity within patients. For instance, the CAG repeat of ATXN3 in patients can be 
comparably low with 55 in number, while the average pathogenic number of repeats is 68. 
For repeat numbers in-between it is not possible to predict weather an individual will have 
MJD symptoms. This overlapping region illustrates that the number of repeats alone is not 
sufficient to predict the development of the disease. In this case, a multifactorial nature is 
seen, which includes single nucleotide polymorphisms (SNPs) within the genome, of which 
many are either not known or they are not well-studied enough to derive relations towards 
the disease. Therefore, an isogenic control population might help to obtain results, which are 
actually related to the gene of interest and not influenced by other non-related factors, 
sophisticating the outcome.  
This assumption is supported by a study published by Reinhardt et al. (2013) investigating 
the link between Leucine-rich repeat kinase 2 (LRRK2) and Parkinson’s Disease (PD) by 
using cultures of midbrain dopaminergic (mDA) neurons differentiated from isogenic human 
induced pluripotent stem cell (hiPSC) lines. The authors stated that since the pathology of 
PD is not only associated with LRRK2 mutations such as G2019S but also with α-synuclein 
(SNCA) and microtubule associated protein tau (MAPT), patients with LRRK2 mutations will 
exhibit variable phenotypes when additional polymorphisms are present in either SNCA or 
MAPT. Additionally the study showed that derivation of hiPSC lines from patients that were 
age and gender matched did not result in closely related gene expression patterns and 
instead displayed large variability in the genetic backgrounds between individuals. But gene 
correction resulted consistently in similar expression pattern within the isogenic LRRK2 
G2019S hiPSC-derived mDA neuronal cell line. Therefore, the authors concluded that it is 
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only possible to detect changes specifically associated with LRRK2 G2019S by generating 
gene corrected isogenic cell lines. 
In the course of this study, a CRISPR/Cas9 system for gene targeting in human neural stem 
was used. The aim was to generate isogenic cell lines with differences in the expression of 
ATXN3 in order to search for differentially expressed genes, which might be attributed to the 
expanded and non-expanded allele or a complete KO of ATXN3. Therefore a multiple 
plasmid system with two major components was incorporated into smNPCs via 
nucleofection: first, the CRISPR/Cas9 knockout plasmids consisting of a pool of three 
plasmids each encoding the Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) 
and second, a homology directed repair (HDR) plasmid providing a specific DNA repair 
template for a double strand break (DSB). The HDR plasmid incorporates a puromycin 
resistance gene for selection of cells where Cas9-induced DNA cleavage has occurred. 
Dependent on the cutting efficiency of Cas 9, multiple monoclonal cell lines derived from two 
patients were gained: cells expressing no ATXN3 (ATXN3_KO), only the non-expanded 
(ATXN3_non-exp) or the expanded allele (ATXN3_exp), respectively. Those monoclonal cell 
lines were selected with puromycin and could be validated by using western blot and PCR.  
In the two KO scenarios either expressing the expanded or the non-expanded allele, ATXN3 
is hemizygously expressed. This does not represent a physiologically occurring state but the 
ATXN3_exp clones could “mimic” a homozygous state of Machado-Joseph Disease in which 
both alleles code for the expanded form only. Furthermore, this system has the advantage 
that, in contrast to most studies investigating ATXN3, the effects and functions of the 
expanded and non-expanded form of ATXN3 can clearly be discriminated without interfering 
with each other.  
Also, in order to gain isogenic clones with variances in the expression of ATXN3, the 
CRISPR/Cas9 system was highly efficient. Over 95 % of selected clones were either KO or 
hemizygous ATXN3 clones and less than 5 % still wild-type clones. The fact that wild type 
clones have been screened might be due to non-homologous integration of the HDR 
plasmids. Additionally to the high efficiency of this CRISPR/Cas9 system, it is further fast and 
straightforward in usage to generate KOs. After nucleofection of the designed plasmids 
(Santa Cruz) into neural precursor cells, within a month, these cells could be selected with 
puromycin, clones were picked and expanded and western blot analysis revealed the state of 
ATXN3 for each clone.   
Since the Cas9 induced break can subsequently lead to wrong corrections by the cellular 
DNA repair machinery, all obtained cell lines were validated regarding their karyotype and 
the DNA sequence of the remaining allele in ATXN3_non-exp and ATXN3_exp clones. No 
karyotypic alterations could be observed and sequencing results revealed that only a minority 
of clones showed alterations in the sequence of the remaining ATXN3 gene. These clones 
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were excluded from further experiments. Such a genome editing system could also bear the 
risk of off-target effects, for instance caused by random HDP plasmid integration, which can 
be detected by whole genome sequencing (WGS). Off-target effects cannot be excluded with 
certainty and testing would be mandatory e.g. for cell therapeutic studies. 
Immunofluorescence stainings showed that all cell lines express the nuclear marker SOX2, 
PLZF, PAX6 and DACH1, nestin as an intermediate filament and the tight junction marker 
ZO-1 for the proliferative state. Also, all cell lines could be differentiated into neurons within 
five weeks expressing β-III tubulin and MAP2ab as well as the astrocytic marker GFAP. 
Additionally, these cultures display an anterior hindbrain identity as only HOXA2 and HOXB2 
were highly expressed. 
The use of neural stem cells allowed, due to their clonal growth and shorter differentiation 
periods, a fast and easy generation of several monoclonal patient-derived cell lines. 
Additionally, by nucleofecting those precursor cells with a CRISPR/Cas9 system in order to 
knock out either both alleles, only the expanded or the non-expanded allele of ATXN3, an 
ideal isogenic control population was created to decipher possible changes in the 
transcriptional regulation of MJD neurons dependent of the presence or absence of ATXN3.  
 
 
5.2 Ataxin 3 as a regulator for the metallothionein-expression 
 
ATXN3 has been proposed to function as a transcriptional co-repressor and to further 
regulate the expression of genes such as MMP2 via histone deacetylation and chromatin 
modification. As a transcription regulator ATXN3 interacts with histones or in transcription 
complexes with co-regulators such as CBP, TBP, NCoR and HDAC3 (Evert et al., 2006; Li et 
al., 2002). Furthermore, it was shown that under oxidative stress, ATXN3 interacts with the 
forkhead box O (FOXO) transcription factor FOXO4 and activates the FOXO4-dependent 
transcription of the manganese superoxide dismutase (SOD2) gene by binding to the SOD2 
gene promoter. In contrast to normal ATXN3, mutant ATXN3 displayed a reduced capability 
to activate the FOXO4-mediated SOD2 expression and interferes with binding of FOXO4 to 
the SOD2 gene promoter (Araujo et al., 2011). Considering the possibility that mutant and 
normal ATXN3 differentially interfere with transcription factors and diversely regulate 
transcriptional regulation, a gene expression analysis with the CRSPR/Cas9-derived cell 
lines was performed in order to screen for differentially expressed genes between 
ATXN3_KO, ATXN3_non-exp and ATXN3_exp neural cultures. 
Comparing the three groups, some genes were depicted with the most dominant differences 
between ATXN3_KO and ATXN3_non-exp, whereas the number of differentially expressed 
genes was lower when comparing ATXN3_KO and ATXN3_exp neurons. Although the 
comparison between ATXN3_KO and ATXN3_non-exp cells helps to reveal functions of 
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ATXN3, the KO situation does not naturally occur. Therefore, the differences in the gene 
expression between cells with the expanded versus non-expanded ATXN3 might be more 
important to reveal a relevant phenotype and to provide the opportunity to make assumptions 
about the gain of function or loss-of-function theory.  
In general, the gene expression analysis revealed only a small number of differentially 
expressed genes, which supports the isogeny of the two patient-derived cell lines. Among 
these few genes a whole cluster of metallothioneins (MT) was discovered. In mammals, MTs 
are divided into four subfamilies (MT-1 – MT-4). All known human MT genes are located in 
the q13 locus on chromosome 16 and encode seven functional MT-1 genes (MT-1A, B, E, F, 
G, H, X) and one functional gene for MT-2, MT-3 and MT-4, respectively. Whereas MT-1 and 
–2 are expressed throughout all tissues of the body, MT-3 is specifically expressed in the 
normal human brain, predominantly in glutamatergic neurons. MT-4 is specifically localized in 
the buccal mucosa and pseudostratified squamous epithelial lining of the uterine cavity 
(Montoliu et al., 2000; Vasak et al., 2011).  
Interestingly, the revealed MT cluster consisted only of MT-1 genes and the MT-2 isoform, 
but no differences in the expression of MT-3 were found. MT-3 differs from MT-1 and -2 as it 
responds to metal levels in neurons differentially, even though the promoter region of MT-3 
has several regions that are similar to the MRE regulating MT-1 and MT-2 levels. An 
explanation for this might be that metal transcription factor 1 (MTF-1), involved in the 
regulation of MT expression, does not bind to the MRE sequence in the MT-3 promoter 
region, suggesting that MT-3 is differently regulated from other metallothioneins 
(Bousleimann et al., 2017). Furthermore, induction of metallothioneins by several inducers 
was found to be due to an increase in MT-1 and -2 gene expression but not MT-3 gene 
expression, because MT-3 cannot be induced in brain (Kramer at al., 1996; Palmiter et al., 
1992; Zheng et al. 1995). These results indicate that in neurons, MT-1 and –2, but not MT-3 
genes are coordinately regulated. 
Under normal conditions and after treatment with 100 µM L-glutamate, the cluster of MTs 
was found to be downregulated in ATXN3_KOs compared to the two other groups in the first 
patient-derived cell line that has been tested. Interestingly, the highest expression was 
observed in ATXN3_exp neurons. This was confirmed by quantitative real-time PCR. 
However, the qPCR data of a set of isogenic clones derived from a second patient cell line 
revealed a different expression pattern for MTs. Still, the expression was lowest in 
ATXN3_KO, but in this cell line the highest expression was found in those cultures with the 
non-expanded allele instead of the expanded one, which would argue for a (partial) loss of 
function of Ataxin 3.  
After the application of 25 µM CdCl2 for 24 h, which is a much stronger stress stimulus than 
100 µM L-glutamate (30 min.), the expression pattern of all MTs was the same in both cell 
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lines with the highest expression in the ATXN3_non-exp neural cultures. This might be 
explained by the fact that the patient one-derived cell line and its generated ATXN3 clones 
could be less prone to the formation of aggregates compared to the patient two-derived cell 
line. Therefore, in the former cell line compensatory mechanisms might still be active, which 
fail to work in the latter one because of a more severe aggregation potential and less 
availability of Ataxin 3 to cope with stress.  
Conclusively, in ATXN3_exp neurons from patient line one forming less aggregates than 
patient line two, there might remain a larger amount of freely available and functional ATXN3 
helping the cells to partially respond to stress. However, after the application of a strong 
stressor such as CdCl2 in a high concentration, the compensatory mechanisms of the less 
aggregation-prone cell line one start to fail as well. In this case, the MT expression pattern 
changes and the highest expression was not found in ATXN3_exp neurons anymore but in 
ATXN3_non-exp neurons, which is the same expression pattern in ATXN3 clones generated 
from patient two.  
This is the first time that an upregulation of metallothioneins is associated with Ataxin 3, a 
link that was revealed by doing a gene expression analysis of isogenic cell lines with 
differences in the state of ATXN3. Evert et al. (2001, 2003) worked on a gene expression 
profile of expanded and non-expanded ATXN3 before but they found other genes to be 
differentially regulated such as the matrix metalloproteinase 2 (MMP-2). Reasons for this can 
be that different cell systems than human neurons were used such as rat mesencephalic 
CSM14.1 clonal cell lines and that some genes such as MMP-2 are not expressed in human 
neurons. This argues for the system used within this study since human neuronal cultures 
were used and only altered in one specific locus to clearly distinguish between expanded and 
non-expanded as well as a loss of Ataxin 3 to screen for genes that are differentially 
expressed. 
 
  
5.3 Ataxin 3 as a regulator of stress responses in human neural cell lines 
 
 
So far, no link between ATXN3 and metallothioneins has been reported. However, it was 
proposed that copper-binding proteins, including MTs, are potential therapeutic targets for 
Huntington’s disease (HD), which belongs together with MJD, to the polyglutamine (ployQ) 
diseases. A pathological hallmark of this disease is an abnormal copper accumulation in the 
postmortem HD brain. It was demonstrated that in vitro copper accelerates the fibrillization of 
an N-terminal fragment of huntingtin with an expanded polyQ stretch (httExon1) in HeLa cells 
and that the overexpression of metallothioneins known to bind copper, protect against 
httExon1 toxicity in a yeast model (Hands et al., 2010).  
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Initially, copper, as a potential metal stressor for the neuronal cultures, was tested in the 
present study as well, but did not show concentration-dependent numbers of surviving cells. 
Instead, the metals CdCl2 and ZnCl2 displayed a linear dose-response curve and were used 
to induce metallothionein expression since MTs play a crucial role in homeostasis of trace 
metals like zinc and detoxification of toxic metals such as cadmium. The oxidative stressor 
rotenone was used due to the protective functions of MTs against oxidative damage and L-
glutamate was chosen as an excitotoxicity-inducer. Typically, MT studies are done by 
application of different metal concentrations and by induction of oxidative stress, but less 
often by induction of excitotoxicicity with glutamate since, in contrast to most of the cell 
systems, this can only be achieved in neuronal cultures. In this study human neuronal 
cultures were used to investigate the influence of L-glutamate-induced excitotoxicty on the 
cell viability of isogenic ATXN3 clones and the associated expression of metallothioneins.   
For the experimental design of the present study all stressors were applied to the cultured 
neurons in three different concentrations for a period of 48h to access cell viability. In 
accordance with the working hypothesis that ATXN3 might be involved in the transcriptional 
regulation of the cellular response to stress, ATXN3_non-exp neurons of both patient-derived 
cell lines displayed the highest number of surviving cells after exposure to different stressors 
and concentrations for 48h. In comparison, ATXN3_KO cells showed a significantly 
decreased cell survival rate and those clones expressing the expanded allele of ATXN3 
displayed a survival rate comparable to those of ATXN3_KO neurons. The numbers of 
surviving cells were all concentration-dependent.  
Similar experiments were conducted in non-clonal cell lines in order to evaluate a 
comparable phenotype. Therefore, two patient-derived non-clonal cell lines and two healthy 
control lines were used for the cell survival assay and indeed in this experiment the healthy 
control neurons displayed a higher cell survival number than the patient-derived cell lines, 
which argues for a similar phenotype as found in the genetically modified cells. 
Since both, the ATXN3_non-exp neurons as well as the healthy control non-clonal neurons, 
displayed a higher cell survival rate than those cell lines with expanded ATXN3, it was further 
determined what consequences arise when aggregates are induced in a healthy control cell 
line by using a lentiviral doxycycline-dependent system overexpressing the truncated 
aggregation-prone form of ATXN3. Interestingly, in the doxycycline treated cells, the 
induction of aggregates lead to a decrease in the cell survival rate compared to those cells 
under normal culture condition without addition of doxycycline.  
Additionally, the numbers of surviving cells of the untreated doxycycline—dependent and 
non-dependent controls were compared and no differenced were found. This might indicate 
that the aggregates inherently are not toxic and not responsible for neuronal cell death within 
the cell survival assay. All these observations lead to the assumption that the depletion due 
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to recruitment of expanded ATXN3 into nuclear inclusions or a KO of ATXN3 and thus the 
failure of functionality of the protein hampers the cellular response to stress.  
From the literature it is known that ATXN3 is involved in certain stress responses within the 
cell due to its deubiquitinating and transcriptional regulation functions. For instance, as a 
deubiquitinating enzyme ATXN3 regulates basal level of hsp70 and modulates the hsp70 
protein level in response to a subset of cellular stresses (Reina et al., 2012), it plays a role in 
the FOXO4-mediated SOD2 expression (Araujo et al., 2011) and the presence of misfolded 
and/or aggregated expanded ATXN3 by itself might result in cellular stress (Bichelmeier et 
al., 2007; Breuer et al., 2010).   
The present study suggests a link between the expression of metallothioneins and ATXN3 
and supports the hypothesis that ATXN3 is involved in the regulation of the cellular stress 
response. 
 
 
5.4  Ataxin 3 as a regulator of total ROS and superoxide levels after stress 
application 
 
The hypothesis that MTs function as an antioxidant against reactive oxygen and nitrogen 
species in biological systems has been widely reported. The results of this thesis indicate 
that ATXN3_KO neurons, expressing the lowest amount of MTs, displayed higher amounts 
of total ROS and superoxides compared to ATXN3 expressing cells. Neurons with the non-
expanded allele of ATXN3, expressing the highest amount of MTs, showed the lowest levels 
of total ROS and superoxides. Since the expression levels of MTs were dependent on the 
presence or absence of ATXN3, this indicates a functional role of ATXN3 in the response to 
cellular stress by regulating the MT expression, which in turn regulate the total ROS and 
superoxide levels. The function of MTs as proteins that protect against oxidative stress is 
especially important for the brain since it is highly susceptible to oxidative stress due to the 
high levels of oxygen consumption.  
Moreover, cells in the brain contain high levels of zinc, elucidating the importance of MT in 
the central nervous system, since MTs are responsible for metal homeostasis. More than a 
thousand proteins have been discovered by human genome analyses that possibly contain 
zinc-binding motifs (Brayer et al., 2008). However, the majority binds zinc tightly, and hence 
might not be able to contribute to fast zinc dynamics in the cell. In contrast, other proteins, 
such as MTs, contain highly redox state sensitive zinc-binding sites (Cousins et al., 2006; 
Chung et al., 2007; Krezel et al., 2007; Maret, 2008; Pedersen et al., 2009). When cells are 
exposed to reducing conditions or when cellular free zinc levels rise, MTs may bind more 
zinc. Vice versa, under oxidative stress conditions or during signaling events involving ROS 
generation, MTs may act as zinc-donors, increasing the availability of free zinc (Chung et al., 
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2007).  
Studies using a cell-free system have demonstrated the ability of MTs to function as free 
radical scavengers (Abel and Deruiter, 1989; Cai et al., 2000; Thornalley and Vasak, 1985). 
Other studies suggested that MTs scavenge a variety of ROS including hydroxyl radicals and 
superoxide anions, nitric oxide radicals, radicals of reactive nitrogen species and hydrogen 
peroxide when oxidative stress levels increase (Kumari et al., 2006; Pedersen et al., 2009; 
Sato and Bremner, 1993; Thirumoorthy et al., 2011).  
The majority of ROS inside the cell is produced in mitochondria as a consequence of the 
electron transport chain, the major cellular mechanism of ATP production. Correspondingly, 
MT-1/2 isoforms have mainly been found in cellular cytoplasm and in some organelles, with 
predominant expression in mitochondria (Banerjee et al. 1982; Dziegiel et al., 2016). 
Antioxidant defense is a major task of cells and considered to be critical in the pathogenesis 
of most neurodegenerative diseases as well as in ageing. Defects in mitochondrial and 
peroxiosomal detoxification are followed by an increase of ROS levels, which has been 
demonstrated to trigger neurodegeneration (Halliwell, 2006; Reddy and Beal, 2005).  
Concluding, the absence of functional ATXN3 in ATXN3_KOs and ATXN3_exp neurons and 
the correlated dysregulation of MTs might bear severe consequences for the cell including 
neurodegeneration.  
 
 
5.5 Model of the Ataxin 3 activated, metal regulatory transcription factor 1-
dependent metallothionein gene expression  
 
The ability of cells in the body to respond to various stressors is crucial for their survival. 
There is a large number of proteins, enzymes and transcriptional factors known which 
participate in stress responses, including ATXN3. The results of this thesis showed that a 
cluster of metallothioneins is downregulated in ATXN3_KO and ATXN3_exp neurons 
compared to those cells expressing the non-expanded allele of ATXN3.  
As discussed before, both ATXN3 and metallothioneins play an important role for the cells 
appropriate reaction towards stress. This was evidenced by cell viability assays, showing that 
after treatment of neurons with metal, oxidative and excitotoxic stressors, the number of 
surviving cells was highest in neurons with the non-expanded allele of ATXN3 and lowest in 
ATXN3_KO cells, whereas the cells with the expanded allele showed numbers of surviving 
cells in-between. Vice versa and consistently, after applying oxidative stress to the neuronal 
cultures, the formation of reactive oxygen species and superoxides was lowest in 
ATXN3_non-exp cells and highest in KO cells.  
The present results indicate that ATXN 3 is apparently required for appropriate induction of 
-Discussion- 
_____________________________________________________________________________________________________ 
 80 
MT expression. A possible hypothesis how ATXN3 regulates the expression of MTs is that 
ATXN3 interacts with a stress sensor (e.g. transcription factor). Within the ATXN3_non-exp 
neurons the coordinated regulation of MT expression helps to prevent the cell from damage, 
thus regulating homeostasis. In the disease situation, in accordance with the loss of function 
theory, expanded ATXN3 is sequestered in nuclear inclusions and further recruits non-
expanded ATXN3 into NIs, reducing the amount of free available ATXN3 within the cell. To a 
certain extent this mimics a KO situation of ATXN3. In both cases, ATXN3 is hampered in its 
functions and fails to upregulate MTs. As a consequence, neurons suffer from stress and 
eventually degenerate (Fig. 5.1).  
 
Figure 5.1: Scheme of a 
possible ATXN3 activated MTF-
1-dependent stress response 
The upper panel depicts the 
normal situation of a healthy cell 
to copy with cell stress. An 
interaction of MTF-1 and ATXN3 
e.g. the ATXN3-mediated 
deubiquitination of MTF-1 might 
lead to an upregulation of MT 
genes due to transcriptional 
regulation of ATXN3. This stress 
response facilitates cell 
homeostasis and ensures 
neuronal survival. The lower 
panel displays the failure of MT 
upregulation under ATXN3 disease or KO condition. ATXN3 is captured and recruited into nuclear inclusions and 
thus not available for the cell to fulfill its biological functions. Hence, there is no interaction with MTF-1 possible, 
resulting in a failure of MT gene upregulation. This might cause cellular stress and neurodegeneration. 
 
 
It is known from literature that the expression of metallothineins is regulated by the 
transcription factor metal regulatory transcription factor 1. MTF-1 was identified in 1988, as a 
candidate protein for zinc-dependent binding of promoters containing a metal-responsive 
element (MRE; Westin and Schaffner, 1988). A few years later, in 1993 MTF-1 was cloned 
and further characterized (Radtke et al., 1993).  MTF-1 is composed of 753 amino acids and 
contains six-zinc finger motifs. The protein is ubiquitously expressed and involved in cellular 
adaptation to various stress conditions, such as exposure to heavy metals, hypoxia and 
oxidative stress (Bonaventura et al., 2015; Lichten et al., 2011; Rutherford et al., 2004; 
Saydam et al., 2003). MTF-1 is a nucleocytoplasmic shuttling protein, which accumulates in 
the nucleus upon heavy metal exposure. Within the nucleus it binds DNA, recruits different 
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co-activators and was also shown to often rely on other transcription factors for the 
expression of certain target genes (Grzywacz et al., 2015; Ruttkay-Nedecky et al., 2013; 
Smirnova et al., 2000).  
MTF-1 controls the expression of metallothioneins (MTs) after metal or oxidative stress, 
thereby maintaining the cellular homeostasis (Grzywacz et al., 2015; Ruttkay-Nedecky et al., 
2013). Activation of metallothionein gene expression by MTF-1 is achieved by multiple MRE 
(metal response element) sequences of core consensus TGCRCNC upstream of the MT 
genes in the promoter regions of MT1 and MT2 genes (Palmiter 1994; Radtke et al., 1995; 
Saydam et al., 2003). Experiments with MTF-1 null-mutant mice revealed that MTF-1 is an 
essential gene, as these mice died in utero due to degeneration of the liver and further did 
not express MT1 and MT2 genes leading to an increased susceptibility to metal stress 
(Günes et al., 1998).  
In order to exclude other factors than MTF-1 that might influence the expression of MTs, the 
comprehensive gene set enrichment analysis web server “Enrichr” was used to search for 
factors that were associated with the expression of MTs. Except MTF-1 and aryl hydrocarbon 
receptor (AHR), non of the revealed factors displayed significant expression levels in the 
gene expression study with isogenic neurons analyzed in this study. Since AHR was 
exclusively associated with MT2 in one study by Sato et al. (2013), it was excluded and MTF-
1 was chosen as a possible candidate for mechanistic studies. 
In order to initiate the expression of metallothioneins, MTF-1 binds to MREs upstream of the 
metallothionein genes. Therefore, MTF-1 has to migrate into the nucleus, which was shown 
for a VSV-tagged lentiviral overexpression construct of MTF-1 (MTF-1_VSV) by performing a 
fractioning protocol, separating total protein lysates into nuclear and cytoplasmic fractions. 
Under basal conditions MTF-1 is present in the cytoplasm and nucleus. After treatment with 
25 µM CdCl2 the amount of MTF-1_VSV increased within the nucleus and decreased within 
the cytoplasm, indicating a functional response towards stress. Additionally, the highest 
amount of the tagged protein MTF-1 was found in the ATXN3_non-exp clones, less was 
found in the ATXN3_exp cells and the KO cells displayed the lowest amount of MTF-1.  
As stated before, qPCR results revealed no differences in the cDNA levels of MTF-1 in the 
isogenic neuronal cell lines, suggesting post-translational modifications of the transcription 
factor MTF-1 as a mechanistic explanation for the ATXN3-dependent regulation of the MT 
expression. The theory emerged that ATXN3 might deubiquitinate MTF-1 under stress 
conditions and thereby preventing it from proteasomal degradation to fulfill its task as a 
regulator of metallothionein expression. In ATXN3_exp and ATXN3_KO cells, 
deubiquitination of MTF-1 might fail, because of the dysfunction of ATXN3, resulting in the 
degradation of MTF-1 by the proteasome and the subsequent disturbance in the 
metallothionein expression. 
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Accordingly, an increased proteasomal degradation of MTF-1 in ATXN3_exp and 
ATXN3_KO neurons should reveal a lower amount of the protein MTF-1 within these cells 
compared to ATXN3 non-exp neurons. To determine the protein stability of overexpressed 
MTF-1_VSV for all cell lines, a cycloheximide chase was performed. Cycloheximide blocks 
the synthesis of new proteins, enabling the observation of protein degradation over time and 
the amount of remaining protein can be detected via western immuno blot. Indeed, after 24h 
and 48h ATXN3_KO neurons revealed a decreased protein stability of MTF-1_VSV than the 
neurons with the non-expanded allele, which might indicate that ATXN3 is involved in 
posttranslational modifications of MTF-1.  
Restoring MTF-1 levels in ATXN3_KO and ATXN3_exp neurons to normal levels should 
improve cell survival. Therefore, neuronal cultures were transduced with a doxycycline-
dependent lentivirus overexpressing VSV-tagged MTF-1. After five weeks of differentiation, 
the cell viability was evaluated after exposure to CdCl2 at different concentrations to access 
neuronal survival rates. MTF-1_VSV expressing ATXN3_non-exp as well as ATXN3_KO but 
not in ATXN3_exp cells displayed significantly improved numbers of cell survival after 
treatment with 10 µM CdCl2.  
To conclude it was shown that the steady state amount of MTF-1 stability was highest in 
ATXN3_non-exp neurons compared to ATXN3_KO and ATXN3_exp neurons by doing a 
cycloheximide chase to determine protein stability. Also, a cell survival assay revealed that 
by overexpressing a VSV-tagged form of MTF-1, the number of surviving cells improved in 
ATXN3_KO and ATXN3_non-exp neurons. So far these are preliminary data and no 
conclusions can be made if this is actually related to the deubiquitinating function of ATXN3. 
Future experiments need to be done to reveal the ubiquitinating status of each cell line and 
to determine if there is an interaction between ATXN3 and MTF-1.  
 
 
5.6 The role of metallothionein expression in neurodegenerative diseases 
 
The brain is highly susceptible to oxidative stress, which increases with age and can 
therefore be considered as a major causative factor in neurodegenerative diseases. 
Furthermore, the brain contains a large amount of zinc, an essential trace metal whose 
dysregulation of homeostasis has been associated with neurodegeneration as well (Juárez-
Rebollar et al., 2017). Metallothioneins are important for the regulation of both processes, 
scavenging free radicals to prevent oxidative stress and zinc homeostasis, hence showing 
the importance of MT in the central nervous system. Consistently, different studies have 
depicted that oxidative damage and abnormal Zn concentrations are associated with the 
pathophysiology of neurodegenerative diseases (Huntington's disease, Alzheimer’s disease 
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and Parkinson’s disease) and other brain disorders such as cerebral ischemia and epilepsy 
(Carrasco et al., 2006; Hands et al., 2010; Juárez-Rebollar et al., 2017; Kim et al., 2012).  
As mentioned before, there is no evidence in the literature that metallothioneins are 
associated with ATXN3 and MJD. However a link between MTs and another polyQ disease, 
Huntngton’s disease (HD), was found. For the pathology of HD a dysregulation of copper 
homeostasis seems to be crucial. Hands et al. (2010) showed that in vitro copper accelerates 
the fibrillization of an N-terminal fragment of huntingtin with an expanded polyQ stretch and 
polyQ aggregation and that overexpression of MTs in mammalian cells significantly reduced 
polyQ aggregation and toxicity.  
In reactive astrocytes of patients with Alzheimer’s disease, an overinduction of MT-1 and MT-
2 has been observed, which was stimulated primarily by the presence of free radicals, metal 
ions, and cytokines. This overinduction was considered to be a cellular defense mechanism 
against inflammatory signals supporting the idea of MT to be neuroprotective (Hidalgo et al., 
2001). Furthermore, a study by Valko et al. (2007) suggested that especially upregulated 
MT-1 in reactive astrocytes has a neuroprotective effect in AD, directly by decreasing the 
neurotoxicity of Aβ and indirectly due to inhibition of Aβ-induced microglial activation by MT-1 
and consequential neurotoxicity.   
With regard to MJD, especially the recruitment of ATXN3 by dysfunctional expanded ATXN3 
into nuclear inclusions and the subsequent dysregulation of metallothioneins within the 
ATXN3_exp neurons, provides a possible explanation why reactive oxygen species 
accumulate within patients neurons, enhancing neurodegenerative effects in MJD (Araujo et 
al., 2011; de Assis et al., 2017; Pacheco et al., 2013; Weber et al., 2014). This would also 
argue for MJD to account for a loss of function disease. By overexpressing the aggregation-
prone truncated form of ATXN3 into a healthy control cell line, aggregates were formed, 
which were not toxic per se, but those cells forming aggregates showed a lower number of 
surviving cells after application of different stressors than those cells without aggregates. In 
accordance with a loss of function ATXN3 is sequestered into these aggregates and is thus 
hampered in its function to cope with cellular stress by regulating the metallothionein 
expression, which might lead to cell death and neurodegeneration.  
Metallothioneins are important for the homeostasis of essential metals such as zinc, the 
detoxification of metals such as cadmium and for scavenging of reactive oxygen species 
such as ROS and superoxides. Potentially, all these processed might be disturbed if Ataxin 3 
fails to regulate the expression of metallothioneins e.g. due to an interaction with MTF-1. 
As a consequence it is mandatory to find an ATXN3-independent way to regulate the 
expression of metallothioneins in patients suffering from MJD. To this account different 
approaches might apply e.g. to avoid exposition to certain noxa, to control for a balanced 
supplementation of trace metals due to nutrients and potential therapeutic drugs. Possible 
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noxa to avoid can be heavy metals such as cadmium and mercury, and also exogenous 
ROS produced from pollutants, tobacco, smoke, drugs, xenobiotics, or radiation. Trace 
metals that are important for health and regulated by metallothioneins are for example iron, 
zinc, copper and manganese.  
There are only a few potential drugs known, which induce the expression of metallothioneins:  
the polyphenol compound quercetin has been found to increase metallothionein expression 
in a rat model for experimental chronic cadmium nephrotoxicity (Morales et al., 2006), the 
açai fruit has been demonstrated to influence expression of MTs in Drosophila (Sun et al., 
2010) as well as the neuroprotective drug resveratrol increasing MT protein levels by 65% in 
the hippocampus of rats following ischemic damage (Yousuf et al., 2009).  
The latter, resveratrol is a polyphenolic stilbene that is widely distributed in red grapes, 
berries, and nuts with low bioavailability. It is known to cross the blood-brain barrier and has 
been shown to be neuroprotective in Huntington’s Diseasae, belonging to the polyglutamine 
diseases (Parker et al., 2005). Resveratrol was shown to rescue mutant polyglutamine 
cytotoxicity in nematode and mammalian neurons (Parker et al., 2005), to improve motor 
deficits and imbalance in SCA3 transgenic mice by pharmacological activation of sirtuin1 
(SIRT1), to protect against cell death in primary cortical neurons containing truncated ataxin-
3 with 79 glutamine repeats and to alleviate oxidative stress induced neurotoxicity in cell and 
Drosophila models of MJD (Cunha-Santos et al., 201; Wu et al., 2017).  
In conclusion, MTs are involved in a number of diseases in the central nervous system, 
indicating a multifunctional role over a wide range of cellular processes. Therefore, future 
studies on the expression and regulation of MT genes are mandatory to elucidate the 
molecular mechanisms involving MT in the nervous system and their role is in the 
pathophysiology of brain disorders. Within this study, a new approach is suggested 
comprising a possible regulation of the expression of metallothioneins by ATXN3. It was 
shown that depletion of ATXN3 due to nuclear inclusions or a KO, in accordance with the 
loss of function hypothesis, leads to a decreased expression of metallothioneins, 
accompanied by a decreased response to cellular stress and an impaired regulation of total 
ROS as well as superoxides, both facilitating neurodegeneration. 
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5.7  General conclusion 
 
This thesis introduces isogenic CRISPR/Cas9-mediated iPSC-derived isogenic neural 
precursor cell lines with different allele expression profiles of ATXN3 for the study of its role 
as a transcriptional regulator and as a mediator of cellular stress. These cell lines could be 
differentiated into mature neurons and the present results revealed that ATXN3 plays an 
important role in the transcriptional regulation of the metallothionein expression in these 
neurons. Also, the regulation of MT expression by ATXN3 seems to be important to mediate 
the cellular response to metal, oxidative and excitotoxic stressors. Vice versa, the depletion 
of ATXN3 in ATXN3_KO and partially loss within ATXN3_exp neurons led to an impaired 
response of neuronal cultures to cellular stress resulting in cell death. Additionally, ATXN3 
seems to be important for the cell to cope with total ROS and superoxides after exposure of 
neuronal cultures to different forms of cellular stress. 
The upregulation of MT gene expression as a response of cells towards stress might be 
mediated by an interaction between ATXN3 and the transcription factor MTF-1. The more 
precise underlying mechanism remains to be demonstrated. However, this study supports 
the idea that ATXN3 is involved in the transcriptional regulation of metallothioneins and thus 
fulfills an important part in regulating the cellular stress response. It is further suggested that 
an impaired function of ATXN3 and consequently a dysregulation of the MT gene cluster 
leads to an increased susceptibility towards stress, which might contribute to the 
pathogenesis of Machado-Joseph-Disease. 
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6. Abbreviations 
 
Abbreviation Full name 
AA Ascorbic acid 
AD Alzheimer’s Disease 
ATXN3 Ataxin 3 
cAMP  Cyclic adenosine monophosphate 
Cd Cadmium 
CHIP C-terminus of Hsc70 interacting protein  
CNS Central nervous system 
CRISPR Clustered regulatory interspaced palindromic repeats 
Dach1 Dachshund homolog 1 
DABCO 1,4-Diazabicyclo[2.2.2]octan 
DAPI 4',6-Diamidino-2-phenylindole 
DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
DMSO Dimethyl suphoxide 
DEPC Diethyl pyrocarbonate  
DMSO Dimethyl sulfoxide 
dNTPs  Nucleoside triphosphate 
Dox Doxycycline 
DSB Double strand break  
DUB Deubiquitinating enzyme 
EDTA  Ethylenediaminetetraacetic acid 
EF1α Flongation factor α 
EGF Epidermal growth factor 
ER Endoplasmatic reticulum 
ERAD Endoplasmatic reticulum associated degragdation 
FCS Fetal calf serum 
FGF2 Fibroblast growth factor 2 
GFAP Glial fibrillary acidic protein 
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Abbreviation Full name 
hES cell Human embryonic cell 
HD Huntington’s Disease 
hPS cell  Human pluripotent stem cell 
HDR Homology-directed repair  
HEK Human embryonic kidney 
ICC Immunocytochemistry 
ICM Inner cell mass 
Hsp Heat shock protein 
iPS cell  Induced pluripotent stem cell 
IRES Internal ribosomal entry site 
Ln Laminin 
ltNES  cell long-term self-renewing neuroepithelial stem cell 
MAP Microtubuli-associated protein 
mDA Midbrain dopaminergic neurons 
MEF Mouse embryonic fibroblast 
MJD  Machado-Joseph disease 
GT GelTrex 
mRNA  messenger RNA 
PAGE  Polyacrylamid gel electrophoresis 
PAX6  Paired box 6 
PBS  Phosphate buffered saline 
PCR Polymerase chain reaction 
PD Parkinson’s Disease 
PFA  Paraformaldehyde 
PLZF  Promyelocytic leukemia-associated zinc finger 
PO  Poly-ornithine 
polyQ Poly-glutamine 
puroR Puromycin resistance 
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Abbreviation Full name 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
RT-PCR  Reverse-transcriptase PCR 
SCA3  Spinocerebellar ataxia type 3 
SDS Sodium dodecyl sulphate 
SOX2  Sex determing region Y-box 2 
TALEN Transcription activator-like effector nuclease 
TC  Tissue culture 
TE  Trypsin/EDTA 
TEMED  Tetramethylethylenediamine 
tetOn  Tetracycline regulatable gene induction system 
TF  Transcription factor 
TI  Trypsin inhibitor 
TREtight  Tetracyclin-responsive element 
Ub Ubiquitin 
VCP Valosin containing protein 
ZO-1  Zona occludens-1 
Zn Zinc 
ZNF Zinc finger 
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7 Abstract 
 
Ataxin-3 (ATXN3), the disease-causing protein for Machado Joseph Disease  (MJD) is 
functionally involved in the protein quality control and transcriptional regulation of various 
genes. Recent data suggest that either conformational changes of the expanded ATXN3 
protein and/or a loss of free available ATXN3 due to recruitment of ATXN3 into aggregates 
leads to the dysregulation of multiple cellular pathways such as ubiquitination or 
transcriptional regulation. In this study, induced pluripotent stem cells (iPSCs) were used to 
decipher the influence of expanded and/or lost ATXN3 on gene expression in patient-specific 
neurons. To that end isogenic iPSC-derived neural stem cell lines were generated, 
expressing the normal (ATXN3_non-exp), the expanded (ATXN3_exp) or no ATXN3 
(ATXN3_KO) using CRISPR/Cas9-mediated gene editing. This approach allowed a direct 
comparison of the gene expression profiles between the expanded/KO and non-expanded 
allele of ATXN3 within an isogenic genetic background. By transcriptional profiling of neurons 
generated from these lines identified several genes were identified, which were dysregulated 
in ATXN3_exp and ATXN3_KO neurons. Among those a cluster of metallothioneins (MTs) 
was found, which was significantly downregulated in ATXN3_exp and ATXN3_KO neurons 
compared to those cells with the non-expanded form of ATXN3. Physiologically, MTs are 
important regulators of cell homeostasis and participate in an array of protective responses 
against oxidative, metal and excitotoxic stress. Consequently, it was discovered that 
ATXN3_exp and ATXN3_KO neurons are more susceptible to several types of cellular 
stress. Furthermore, these neurons displayed a higher level of total ROS and superoxide 
under oxidative stress compared to ATXN3_non-exp neurons.  
As a possible underlying mechanism this thesis suggests a posttranslational interaction 
between ATXN3 and metal transcription factor 1 (MTF-1) for the regulation of the gene 
expression of MTs via the deubiquitinating function of ATXN3. So far, increased MTF-1 
protein levels in ATXN3_non-exp neurons in comparison to ATXN3_KOs support this idea. 
But these are preliminary data and whether ATXN3 regulates responses to various stressors 
by interacting with MTF-1 remains to be demonstrated, however in the frame of this work a 
strong genetic neuronal model was generated that supports a correlation between ATXN3 
and MT expression. Furthermore, this work confirms that ATXN3 plays an important role in 
regulating the cellular stress response and that an increased susceptibility towards stress 
and the correlating decreased anti-oxidative defense contributes to neuronal cell death and 
thus to the pathogenesis of Machado Joseph Disease. 
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8 Zusammenfassung 
 
Ataxin-3 (ATXN3), das Protein, welches für die Entstehung der Machado Joseph Krankheit 
verantwortlich ist,  ist funktionell an der zellulären Qualitätskontrolle von Proteinen und der 
transkriptionellen Regulation von verschiedenen Genen beteiligt. Bisherige Studien 
unterstützen die Annahme, dass eine Änderung in der Konformation des Proteins und/oder 
der Verlust von nicht-expandiertem ATXN3 durch die Rekrutierung in nucleäre Inklusionen 
zu einer Dysregulierung von diversen zellulären Prozessen so wie der Ubiquitinierung oder 
der transkriptionellen Regulation führen.  
In der vorliegenden Arbeit wurden induzierte pluripotente Stammzellen (iPS-Zellen) 
verwendet, um den Einfluss von expandiertem ATXN3 oder einem KO von ATXN3 auf die 
Genexpression innerhalb patientenspezifischer Neurone zu entschlüsseln. Dafür wurden, 
unter Verwendung einer CRISPR/Cas9-vermittelten Geneditierung,  isogene iPS-abgeleitete 
Stammzellen generiert, welche entweder das normale (ATXN3_non-exp), das expandierte 
(ATXN3_exp) oder einen KO von ATXN3 (ATXN3_KO) ausbilden. Die resultierenden 
isogenen Zelllinien erlauben einen direkten Vergleich der Genexpression zwischen Zellen, 
welche entweder die expandierte/KO oder normale Form von ATXN3 exprimieren. Durch 
Genexpressionsanalysen der durch diese Zelllinien abgeleiteten Neurone konnten einige 
Gene identifiziert werden, welche in ATXN3_exp- und ATXN3_KO-Neuronen dysreguliert 
waren. Unter diesen befand sich eine Gruppe von Metallothioneinen, welche im Vergleich zu 
ATXN3_nicht-expandierten Neuronen in ATXN3_expandierten und ATXN3_KO  signifikant 
runterreguliert waren. 
Physiologisch gesehen sind Metallothioneine wichtige Regulatoren der Zellhomöostase und 
der zellulären Antwort auf oxidativen, excitotoxischen und  Metallstress. Dementsprechend 
ergaben Ergebnisse dieser Arbeit eine erhöhte Anfälligkeit auf Stress in Neuronen, die 
entweder den KO von ATXN3 oder die expandierte Form ausbildeten. Außerdem wurde in 
diesen Zellen ebenfalls erhöhte Level an reaktiven Sauerstoffspezies and Superoxiden 
gefunden.  
Ein möglicher Mechanismus dafür könnte eine posttranslationale Interaktion zwischen 
ATXN3 und dem Transkriptionsfaktor MTF-1 sein, wobei die deubiquitinierende Funktion von 
ATXN3 eine wichtige Rolle spielen könnte. Vorläufige Ergebnisse dieser Arbeit zeigen eine 
erhöhte MTF-1-Proteinstabilität in Neuronen mit dem nicht-expandiertem ATXN3 im 
Vergleich zu den anderen Zelllinien, was diese Hypothese unterstützt. Für eine genauere 
Untersuchung dieses Mechanismus müssen weitere Experimente vorgenommen werden. 
Dennoch wurde im Rahmen dieser Arbeit ein genetisch editiertes Zellmodell geschaffen, 
welches einen Zusammenhang zwischen der Genexpression von ATXN3 und der 
Expression von Metallothioneinen darstellt. Außerdem unterstützen die Ergebnisse dieser 
-Zusammenfassung- 
_____________________________________________________________________________________________________ 
 91 
Arbeit die Involvierung von ATXN3 in der Regulierung von zellulärem Stress und dass eine 
erhöhte Stressanfälligkeit der Zelle und einer damit einhergehenden Verringerung der 
antioxidativen Abwehr zu Zelltod und folglich zu der Pathogenese von Machado Joseph 
Krankheit beitragen kann. 
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